US5580888A - Styryl derivatives as anti-inflammatory agents - Google Patents

Styryl derivatives as anti-inflammatory agents Download PDF

Info

Publication number
US5580888A
US5580888A US08/462,118 US46211895A US5580888A US 5580888 A US5580888 A US 5580888A US 46211895 A US46211895 A US 46211895A US 5580888 A US5580888 A US 5580888A
Authority
US
United States
Prior art keywords
group
cyclopentyloxy
alk
methoxyphenyl
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/462,118
Inventor
Graham J. Warrellow
Ewan C. Boyd
Rikki P. Alexander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Priority to US08/462,118 priority Critical patent/US5580888A/en
Assigned to CELLTECH, LIMITED reassignment CELLTECH, LIMITED CROSS-REFERENCE OF ASSIGNMENT ORIGINALLY RECORDED IN S.N. 08/172,047 AT REEL 7023 FRAME 0720 Assignors: ALEXANDER, RIKKI PETER, BOYD, EWAN CAMPBELL, WARRELLOW, GRAHAM JOHN
Assigned to CELLTECH THERAPEUTICS LIMITED reassignment CELLTECH THERAPEUTICS LIMITED CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: CELLTECH LIMITED
Application granted granted Critical
Publication of US5580888A publication Critical patent/US5580888A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/243—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/247—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/253—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C07C65/26—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • This invention relates to a novel series of styryl derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their use in medicine.
  • adenosine 3', 5'-cyclic monophosphate adenosine 3', 5'-cyclic monophosphate
  • the cellular levels of cAMP are regulated by mechanisms which control synthesis and breakdown.
  • the synthesis of cAMP is controlled by adenylyl cyclase which may be directly activated by agents such as forskolin or indirectly activated by the binding of specific agonists to cell surface receptors which are coupled to adenylyl cyclase.
  • the breakdown of cAMP is controlled by a family of phosphodiesterase (PDE) isoenzymes, which also control the breakdown of guanosine 3',5'-cyclic monophosphate (cGMP).
  • PDE phosphodiesterase
  • PDE I-VII the distribution of which varies from tissue to tissue. This suggests that specific inhibitors of PDE isoenzymes could achieve differential elevation of cAMP in different tissues, [for reviews of PDE distribution, structure, function and regulation, see Beavo & Reifsnyder (1990) TIPS, 11:150-155 and Nicholson et al (1991) TIPS, 12: 19-27].
  • PDE IV inhibitors have met with limited success to date, in that many of the potential PDE IV inhibitors which have been synthesised have lacked potency and/or have been capable of inhibiting more than one type of PDE isoenzyme in a non-selective manner. Lack of a selective action has been a particular problem given the widespread role of cAMP in vivo and what is needed are potent selective PDE IV inhibitors with an inhibitory action against PDE IV and little or no action against other PDE isoenzymes.
  • X is --O--, --S-- or --N(R 6 )--, where R 6 is a hydrogen atom or an alkyl group.
  • R 2 is an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group
  • R 3 and R 4 which may be the same or different, is each a group --(CH 2 ) n Ar, where Ar is a monocyclic or bicylic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms and n is zero or an integer 1, 2 or 3;
  • R 5 is a hydrogen atom or an optionally substituted alkyl group; and the salts, solvates, hydrates and N-oxides thereof.
  • the compounds of formula (1) exist as geometrical isomers and the invention extends to all such individual isomers and mixtures thereof.
  • Formula (1) and the formulae hereinafter should be understood to include all individual isomers and mixtures thereof, unless stated otherwise, and even though only one isomer may be depicted.
  • Y is a halogen atom it may be for example a fluorine, chlorine, bromine or iodine atom.
  • R 1 may be, for example, an optionally substituted straight or branched alkyl group, for example, an optionally substituted C 1-6 alkyl group, such as a methyl, ethyl, n-propyl, or i-propyl, group.
  • Optional substitutents which may be present on R 1 groups include one or more halogen atoms, e.g. fluorine, or chlorine atoms.
  • Particular substituted alkyl groups include for example --CH 2 F, --CH 2 Cl, --CHF 2 , --CHCl 2 , --CF 3 or --CCl 3 groups.
  • Alkyl groups represented by R 2 or R 5 in the compounds of formula (1) include optionally substituted straight or branched C 1-6 alkyl groups, e.g. C 1-3 alkyl groups such as methyl or ethyl groups.
  • Optional substituents on these groups include one, two or three substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or hydroxyl or C 1-6 alkoxy e.g. C 1-3 alkoxy such as methoxy or ethoxy groups.
  • Alkenyl groups represented by R 2 in the compounds of formula (1) include optionally substituted straight or branched C 2-6 alkenyl groups such as ethenyl, propen-1-yl and 2-methylpropen-1-yl.
  • Optional substituents include those described above in relation to the groups R 2 and R 5 .
  • R 2 in the compounds of formula (1) is an optionally substituted cycloalkyl or cycloalkenyl group it may be for example a C 3-8 cycloalkyl group such as a cyclobutyl, cyclopentyl or cyclohexyl group or a C 3-8 cycloalkenyl group containing for example one or two double bonds such as 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2,4-cyclopentadien-1-yl, 2-cyclohexen-1-yl, 3-cyclohexen-1-yl, 2,4-cyclohexadien-1-yl or 3,5-cyclohexadien-1-yl group, each cycloalkyl or cycloalkenyl group being optionally substituted by one, two or three substituents selected from halogen atoms, e.g.
  • C 1-6 alkyl e.g. C 1-3 alkyl such as methyl or ethyl, hydroxyl or C 1-6 alkoxy e.g. C 1-3 alkoxy such as methoxy or ethoxy groups.
  • Alkyl groups represented by R 6 in compounds of formula (1) include straight or branched C 1-6 alkyl groups, e.g. C 1-3 alkyl groups such as methyl or ethyl groups.
  • the groups R 3 and/or R 4 may each independently be a group --Ar, --CH 2 Ar, --(CH 2 ) 2 Ar or --(CH 2 ) 3 Ar.
  • Monocyclic or bicyclic aryl groups represented by the group Ar in compounds of formula (1) include for example C 6-12 optionally substituted aryl groups, for example optionally substituted phenyl, 1- or 2-naphthyl, indenyl or isoindenyl groups.
  • Ar contains one or more heteroatoms it may be for example a C 1-9 optionally substituted heteroaryl group containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms.
  • Ar heteroaryl groups may be for example monocyclic or bicyclic heteroaryl groups.
  • Monocyclic heteroaryl groups include for example five- or six-membered heteroaryl groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms.
  • heteroaryl groups represented by Ar include pyrrolyl, furyl, thienyl, imidazolyl, N-methylimidazolyl, N-ethylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolyl, isoindolyl, benzimidazo
  • the heteroaryl group represented by Ar may be attached to the remainder of the molecule of formula (1) through any ring carbon or heteroatom as appropriate.
  • the group Ar when it is a pyridyl group it may be a 2-pyridyl, 3-pyridyl or 4-pyridyl group.
  • it when it is a thienyl group it may be a 2-thienyl or 3-thienyl group, and, similarly, when it is a furyl group it may be a 2-furyl or 3-furyl group.
  • the Ar group is a nitrogen-containing heterocycle it may be possible to form quaternary salts, for example N-alkyl quaternary salts and the invention is to be understood to extend to such salts.
  • quaternary salts for example N-alkyl quaternary salts
  • the invention is to be understood to extend to such salts.
  • pyridinium salts may be formed, for example N-alkylpyridinium salts such as N-methylpyridinium.
  • the aryl or heteroaryl groups represented by Ar in compounds of formula (1) may each optionally be substituted by one, two, three or more substituents [R 7 ].
  • the substituent R 7 may be selected from an atom or group R 8 or --Alk 1 (R 8 ) m wherein R 8 is a halogen atom, or an amino (--NH 2 ), substituted amino, nitro, cyano, hydroxyl (--OH), substituted hydroxyl, cycloalkoxy, formyl [HC(O)--], carboxyl (--CO 2 H), esterified carboxyl, thiol (--SH), substituted thiol, --C(O)Alk 1 , --SO 3 H, --SO 2 Alk 1 , --SO 2 NH 2 13 SO 2 NHAlk 1 , --SO 2 N[Alk 1 ] 2 , --CONH 2 , --CONHAlk 1 , C--ON[Alk 1 ] 2 , --NH
  • R 8 When R 8 is a substituted amino group it may be a group --NH[Alk 1 (R 8a ) m ] [where Alk 1 and m are as defined above and R 8a is as defined above for R 8 but is not a substituted amino, a substituted hydroxyl or a substituted thiol group] or a group --N[Alk 1 (R 8a ) m ] 2 wherein each --Alk 1 (R 8a ) m group is the same or different.
  • R 8 is a halogen atom it may be for example a fluorine, chlorine, bromine, or iodine atom.
  • R 8 is a cycloalkoxy group it may be for example a C 5-7 cycloalkoxy group such as a cyclopentyloxy or cyclohexyloxy group.
  • R 8 is a substituted hydroxyl or substituted thiol group it may be a group --OAlk 1 (R 8a ) m or --SAlk 1 (R 8a ) m respectively, where Alk 1 , R 8a and m are as just defined.
  • Esterified carboxyl groups represented by the group R 8 include groups of formula --CO 2 Alk 2 wherein Alk 2 is a straight or branched, optionally substituted C 1-8 alkyl group such as a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl group; a C 6-12 arylC 1-8 alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; a C 6-12 aryl group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a C 6-12 aryloxyC 1-8 alkyl group such as an optionally substituted phenyloxymethyl, phenyloxyethyl, 1-naphth
  • Alk 1 When Alk 1 is present in or as a substituent R 7 it may be for example a methylene, ethylene, n-propylene, i-propylene, n-butylene, i-butylene, s-butylene, t-butylene, ethenylene, 2-propenylene, 2-butenylene, 3-butenylene, ethynylene, 2-propynylene, 2-butynylene or 3-butynylene chain, optionally interrupted by one, two, or three --O-- or --S--, atoms or --S(O)--, --S(O) 2 -- or --N(R 6 )-- groups.
  • Particularly useful atoms or groups represented by R 7 include fluorine, chlorine, bromine or iodine atoms, or C 1-6 alkyl, e.g. methyl or ethyl, 6 alkylamino, e.g. methylamino or ethylamino, C 1-6 hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, C 1-6 alkylthiol e.g. methylthiol or ethylthiol, C 1-6 alkoxy, e.g. methoxy or ethoxy, C 5-7 cycloalkoxy, e.g. cyclopentyloxy, haloC 1-6 alkyl, e.g.
  • C 1-6 alkylamino e.g. methylamino or ethylamino, amino (--NH 2 ), aminoC 1-6 alkyl, e.g. aminomethyl or aminoethyl, C 1-6 dialkylamino, e.g. dimethylamino or diethylamino, nitro, cyano, hydroxyl (--OH), formyl [HC(O)--], carboxyl (--CO 2 H), --CO 2 Alk 2 [where Alk 2 is as defined above], C 1-6 alkanoyl e.g. acetyl, thiol (--SH), thio C 1-6 alkyl, e.g.
  • sulphonyl (--SO 3 H), C 1-6 alkylsulphonyl, e.g. methylsulphonyl, aminosulphonyl (--SO 2 NH 2 ), C 1-6 alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C 1-6 dialkylaminosulphonyl, e.g. di-methylaminosulphonyl or diethylaminosulphonyl, carboxamido (--CONH 2 ), C 1-6 alkylaminocarbonyl, e.g.
  • methylaminocarbonyl or ethylaminocarbonyl C 1-6 dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, sulphonylamino (--NHSO 2 H), C 1-6 alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, C 1-6 dialkylsulphonylamino, e.g.
  • C 1-6 alkylaminosulphonylamino e.g.
  • two R 7 substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C 2-6 alkylenedioxy group such as ethylenedioxy.
  • a cyclic group such as a cyclic ether, e.g. a C 2-6 alkylenedioxy group such as ethylenedioxy.
  • R 7 substituents may be present at any ring carbon atom away from that attached to the rest of the molecule of formula (1).
  • any substituent may be present at the 2-, 3-, 4-, 5- or 6-positions relative to the ring carbon atom attached to the remainder of the molecule.
  • Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.
  • Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, or isethionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or napsylates, phosphates, sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.
  • alkylsulphonates e.g. methanesulphonates, ethanesulphonates, or isethionates
  • arylsulphonates e.g. p-toluenesulphonates
  • besylates or napsylates phosphates, sulphates, acetates
  • Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.
  • Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.
  • the group Y is preferably an --OR 1 group, especially where R 1 is an optionally substituted ethyl group or, especially, an optionally substituted methyl group.
  • R 1 is an optionally substituted ethyl group or, especially, an optionally substituted methyl group.
  • Especially useful substitutents which may be present on R 1 groups include one, two or three fluorine or chlorine atoms.
  • the group X in compounds of formula (1) is preferably --O--.
  • a particularly useful group of compounds of formula (1) has the formula (2): ##STR3## where R 2 is an optionally substituted cycloalkyl group; R 3 , R 4 , and R 5 are as defined for formula (1); and the salts, solvates, hydrates and N-oxides thereof.
  • R 2 is preferably an optionally substituted cyclopentyl group.
  • R 2 is a cyclopentyl group.
  • the group R 5 is preferably a hydrogen atom.
  • the group R 3 and R 4 in compounds of formulae (1) or (2) is each preferably a --CH 2 Ar group, or, especially an --Ar group.
  • R 3 or R 4 groups in compounds of formulae (1) or (2) include those R 3 or R 4 groups in which Ar is a monocyclic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur, or, in particular, nitrogen atoms, and optionally substituted by one, two or more R 7 substituents.
  • Ar is a monocyclic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur, or, in particular, nitrogen atoms, and optionally substituted by one, two or more R 7 substituents.
  • Ar when the group represented by Ar is a heteroaryl group it is preferably a nitrogen-containing monocyclic heteroaryl group, especially a six-membered nitrogen-containing heteroaryl group.
  • the groups R 4 and R 5 may each be a six-membered nitrogen-containing heteroaryl group.
  • R 4 may be a monocyclic aryl group and R 5 may be a six-membered nitrogen-containing heteroaryl group.
  • the six-membered nitrogen-containing heteroaryl group may be an optionally substituted pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl group.
  • Particular examples include optionally substituted 2-pyridyl, 3-pyridyl or, especially, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl or 3-pyrazinyl.
  • the monocyclic aryl group may be a phenyl group or a substituted phenyl group.
  • R 3 and R 4 is each a pyridyl or, especially, a monosubstituted pyridyl, or preferably a disubstituted pyridyl group, or R 3 is a phenyl or substituted phenyl group and R 4 is a pyridyl or, especially a monosubstituted pyridyl, or preferably a disubstituted pyridyl group.
  • R 3 and/or R 4 when R 3 and/or R 4 is a substituted phenyl group it may be for example a mono-, di- or trisubstituted phenyl group in which the substituent is an atom or group R 7 as defined above.
  • R 3 and/or R 4 group when the R 3 and/or R 4 group is a monosubstituted phenyl group the substituent may be in the 2-, or preferably 3-, or especially 4-position relative to the ring carbon atom attached to the remainder of the molecule.
  • R 3 and/or R 4 is a substituted pyridyl group it may be for example a mono-or disubstituted pyridyl group, such as a mono- or disubstituted 2-pyridyl, 3-pyridyl or especially 4-pyridyl group substituted by one or two atoms or groups R 7 as defined above, in particular one or two halogen atoms such as fluorine or chlorine atoms, or methyl, methoxy, hydroxyl or nitro groups.
  • Particularly useful pyridyl groups of these types are 3-monosubstituted-4-pyridyl or 3,5-disubstituted-4-pyridyl, or 2- or 4-monosubstituted-3-pyridyl or 2,4-disubstituted-3-pyridyl groups.
  • a particularly useful group of compounds according to the invention has the formula (2) wherein R 5 is a hydrogen atom and R 3 and R 4 are as defined for formula (1); and the salts, solvates, hydrates and N-oxides thereof.
  • R 3 is an optionally substituted phenyl, or pyridyl in particular 4-pyridyl, group and R 4 is a pyridyl especially a 4-pyridyl group are particularly preferred.
  • Particularly useful compounds according to the invention are the (E) and (Z) isomers of
  • Compounds according to the invention are selective and potent inhibitors of PDE IV.
  • the ability of the compounds to act in this way may be simply determined by the tests described in the Examples hereinafter.
  • the compounds according to the invention are thus of particular use in the prophylaxis and treatment of human diseases where an unwanted inflammatory response or muscular spasm is present and where the elevation of cAMP levels may be expected to prevent or alleviate the inflammation and relax muscles.
  • Particular uses to which the compounds of the invention may be put include the prophylaxis and treatment of asthma, especially inflamed lung associated with asthma, or in the treatment of inflammatory airway disease, chronic bronchitis, eosinophilic granuloma, psoriasis and other benign and malignant proliferative skin diseases, endotoxic shock, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, atopic dermatitis, urticaria, allergic rhinitis, adult respiratory distress syndrome, diabetes insipidus, allergic conjunctivitis and vernal conjunctivitis.
  • Compounds according to the invention may also elevate cAMP in lymphocytes and thereby suppress unwanted lymphocyte activation in immune-based diseases such as rheumatoid arthritis, transplant rejection and graft versus host disease.
  • the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.
  • compositions according to the invention may take a form suitable for oral, buccal, parenteral or nasal administration, or a form suitable for administration by inhalation or insufflation.
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium glycollate
  • wetting agents
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives.
  • the preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds of formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form.
  • the compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • the compounds of formula (1) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular injection.
  • compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
  • the pack or dispense device may be accompanied by instructions for administration.
  • the quantity of a compound of the invention required for the prophylaxis or treatment of a particular inflammatory condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100 ng/kg to 100 mg/kg, e.g. around 0.01 mg/kg to 40 mg/kg body weight for oral or buccal administration, from around 10 ng/kg to 50 mg/kg body weight for parenteral administration, and around 0.05 mg to around 1000 mg for nasal administration or administration by inhalation or insufflation.
  • the compounds according to the invention may be prepared by the following processes.
  • the symbols Y, R 2 , R 3 , R 4 , R 5 , and X 1 when used in the formulae below are to be understood to represent those groups described above in relation to formula (1) unless otherwise indicated.
  • reactive functional groups for example hydroxy, amino or thiol groups, where these are desired in the final product, to avoid their unwanted participation in the reactions.
  • Conventional protecting groups may be used in accordance with standard practice [see, for example, Green, T. W. in "Protective Groups in Organic Synthesis” John Wiley and Sons, 1981.] It may be that deprotection will form the last step in the synthesis of compounds of formula (1).
  • compounds of formula (1), wherein R 3 and/or R 4 contains a carboxylic group may be prepared by deprotecting the corresponding compound wherein R 3 and/or R 4 contains a protected carboxyl group, such as an oxazolinyl e.g. 4,4-dimethyl-2-oxazolinyl, in the presence of a base, e.g. sodium hydroxide, in an acid solvent, e.g. aqueous hydrochloric acid, at an elevated temperature, e.g. the reflux temperature.
  • a base e.g. sodium hydroxide
  • an acid solvent e.g. aqueous hydrochloric acid
  • Suitable acids include for example phosphoric or sulphonic acids, e.g. 4-toluenesulphonic acid.
  • the reaction may be performed in an inert organic solvent, for example a hydrocarbon such as toluene, at an elevated temperature, for example the reflux temperature.
  • Base catalysed elimination may be performed using for example trifluoroacetic anhydride in the presence of an organic base such as triethylamine at a low temperature e.g. from around 0° C. to ambient temperature, in a solvent such as dichloromethane or tetrahydroduran.
  • reaction conditions used may also cleave the group R 2 in the starting material of formula (4) to yield a compound of formula (1) where R 2 is a hydrogen atom.
  • R 2 is a hydrogen atom.
  • Such compounds may be converted to the required compound of formula (3) by a further process according to the invention using a halide R 2 Hal (where Hal is a halogen atom such as a bromine or chlorine atom) where necessary in the presence of a base such as caesium or potassium carbonate or an alkoxide such as potassium t-butoxide, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide at ambient temperature or above e.g. around 40° C. to 50° C.
  • a halide R 2 Hal where Hal is a halogen atom such as a bromine or chlorine atom
  • a base such as caesium or potassium carbonate or an alkoxide such as potassium t-butoxide
  • Metal atoms represented by Z include, for example, a lithium atom.
  • the reaction may be performed in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at a low temperature, e.g. around -70° C. to ambient temperature.
  • a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at a low temperature, e.g. around -70° C. to ambient temperature.
  • This reaction is particularly suitable for the preparation of compounds of formula (1) wherein R 4 is an electron deficient group such as a 2- or 4-pyridyl group.
  • Reagents R 4 R 5 CHZ are either known compounds or may be prepared, preferably in situ during the above process, by reaction of a compound AlkCH 2 Z [where Alk is an alkyl group such as a n-propyl group] with a compound R 4 R 5 CH 2 where necessary in the presence of a base such as an amine e.g. diisopropylamine using the above-mentioned conditions.
  • Ketones of formula (4) may be prepared by oxidation of a corresponding alcohol of formula (5): ##STR6## using an oxidising agent such as manganese dioxide in a solvent such as dichloromethane at ambient temperature.
  • ketones of formula (4) may be prepared by reaction of a halide of formula (6): ##STR7## [where Hal is a halogen atom such as a bromine or chlorine atom] by halogen-metal exchange with a base such as n-butyllithium, followed by reaction with a nitrile R 3 CN, an acid chloride R 3 COCl or an ester R 3 CO 2 Alk (where Alk is an alkyl group, e.g. a methyl group) in a solvent such as tetrahydrofuran, at a low temperature, e.g. around -70° C., and subsequent treatment with an acid such as hydrochloric acid at e.g. -20° C. to ambient temperature.
  • Hal is a halogen atom such as a bromine or chlorine atom
  • Alcohols of formula (5) may be prepared by reaction of an aldehyde of formula (7): ##STR8## with organometallic compound, such as an organolithium compound R 3 Li, or a Grignard reagent R 3 MgBr, in a solvent, such as tetrahydrofuran, at a low temperature, e.g. around -55° C. to 0° C.
  • organometallic compound such as an organolithium compound R 3 Li, or a Grignard reagent R 3 MgBr
  • Aldehydes of formula (7) may be prepared by alkylation of a corresponding compound of formula (8): ##STR9## using a compound R 2 Hal [where Hal is as previously defined] using the reagents and conditions described herein above for the alkylation of intermediates of formula 4.
  • Halides of formula (6) may be prepared by alkylation of a compound of formula (9): ##STR10## using the reagents and conditions discussed above in relation to the alkylation of aldehydes of formula (8).
  • Halides of formula (9) where X is --O-- may be prepared by oxidation of an aldehyde of formula (10): ##STR11## using an oxidising agent such as 3-chloroperoxybenzoic acid in a halogenated hydrocarbon such as chloroform at a temperature from around 0° C. to room temperature.
  • Aldehydes of formula (8) and halides of formula (10) where X is --S-- or --N(R 6 )-- are either known compounds or may be prepared from known starting materials by methods analogous to those used for the preparation of the known compounds.
  • compounds of formula (1) may be obtained by coupling a compound of formula (11) ##STR12## in a Heck reaction with an organopalladium compound derived from a compound R 4 Hal [where Hal is a halogen atom, such as a bromine atom] and a palladium salt, such as palladium acetate, in the presence of a phosphine such as tri-o-tolylphosphine and a base such as triethylamine at an elevated temperature and pressure.
  • Intermediate alkenes of formula (11) may be obtained by reaction of a corresponding ketone of formula (4) (described herein above) using a Wittig reaction employing a phosphonium salt such as methyltriphenylphosphonium bromide in the presence of a base such as n-butyllithium and in inert solvent such as tetrhydrofuran at, for example, 0° C. to ambient temperature.
  • a phosphonium salt such as methyltriphenylphosphonium bromide
  • a base such as n-butyllithium
  • inert solvent such as tetrhydrofuran
  • a compound of formula (1) may be prepared by dehydrogenation of a compound of formula (12): ##STR13## where R is ahydrogen atom, using a dehydrogenating agent.
  • Suitable dehydrogenation reagents include for example quinones such as 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, in a solvent, e.g. dioxane, at an elevated temperature, e.g. the reflux temperature.
  • Compounds of formula (12) may be prepared by cyclisation of a compound of formula (13) ##STR14## where R is a carboxylic acid [--CO 2 H] group or a reactive derivative thereof; or a nitrile [--CN] or an imine salt with a bifunctional reagent W 1 R 4a W 2 and, where necessary, a compound R 4b W 3 [where W 1 , W 2 and W 3 , which may be the same or different, is each a reactive functional group or a protected derivative thereof; and R 4a and R 4b are components of the heteroaryl group R 4 such that when added together with W 1 , W 2 and W 3 to the group R in compounds of formula (15) the resulting group --RW 1 R 4a W 2 or --RW 1 R 4a W 2 R 4b W 3 constitutes the heteroaryl group R 4 ].
  • Reactive derivatives of carboxylic acids for use in this reaction include acid halides, (e.g. acid chlorides), amides, including thioamides, or esters, including thioesters.
  • Imine salts include for example salts of formula [e.g. --C(OAlk) ⁇ NH 2 + A - , where Alk is a C 1-4 alkyl group and A - is a counterion e.g. a chloride ion].
  • the reactive functional groups represented by W 1 , W 2 or W 3 may be any suitable carbon, nitrogen, sulphur or oxygen nucleophiles.
  • Particular examples include simple nucleophiles such as carbanions [e.g. generated by the coupling of an alkyl group with an organometallic compound], amino, thiol and hydroxyl groups.
  • the cyclisation reaction will initially be performed in a solvent, for example an inert solvent such as a halocarbon, e.g. dichloromethane, an ether, e.g. a cyclic ether such as tetrahydrofuran, or a hydrocarbon, e.g. an aromatic hydrocarbon such as toluene, from a low temperature, e.g. around -70° C., to around the reflux temperature, where necessary in the presence of a base or a thiation reagent, e.g. Lawesson's reagent, followed if necessary by heating, to an elevated temperature, e.g. the reflux temperature.
  • a solvent for example an inert solvent such as a halocarbon, e.g. dichloromethane, an ether, e.g. a cyclic ether such as tetrahydrofuran, or a hydrocarbon, e.g. an aromatic hydrocarbon such as toluene, from
  • compounds of formula (12) wherein R 4 is a benzothiazolyl, benzoxazolyl or benzimidazolyl group may be prepared by reaction of a compound of formula (13) where R is an acid halide, e.g. acid chloride, with a reagent W 1 R 4a W 2 which is 2-aminothiophenol, 2-hydroxyphenol, or 1,2-diaminobenzene respectively in the presence of a base e.g. an organic amine such as pyridine, in a solvent e.g. a halocarbon such as dichloromethane, from around -70° C. to the reflux temperature.
  • a base e.g. an organic amine such as pyridine
  • a solvent e.g. a halocarbon such as dichloromethane
  • a compound of formula (13) where R is an acid halide as described above may be reacted with a compound W 1 R 4a W 2 which is a monoalkylmalonate, e.g. ethyl hydrogen malonate, followed by reaction with a compound R 4b W 3 which is hydrazine to give a compound of formula (1) wherein R 4 is a 5-hydroxypyrazolyl group.
  • the halide of formula (13) may be reacted with a compound W 1 R 4a W 2 which is H 2 NNHCSNH 2 in an aromatic hydrocarbon such as toluene, at an elevated temperature, e.g. around 150° C., followed by treatment with a base, e.g. an inorganic base such as sodium bicarbonate to give a compound of formula (12) wherein R 4 is a 1,2,4-triazolyl-5-thiolate group.
  • a base e.g. an inorganic base such as sodium bicarbonate
  • Intermediate compounds of formula (13) are particularly useful and form a further aspect of the invention.
  • Active derivatives of the acids of formula (13) and other compounds of formula (13) where R is a nitrile or an imine salt may be prepared from the corresponding acids [where R is --CO 2 H] using conventional procedures for converting carboxylic acids to such compounds, for example as described in the Examples hereinafter.
  • Acids of formula (13) [where R is --CO 2 H] may be prepared by hydrolysing a diester of formula (14) ##STR15## where Alk is a C 1-4 alkyl group, e.g. an ethyl group, with a base, e.g. sodium hydroxide, in a solvent, e.g. dioxane, at an elevated temperature, e.g. the reflux temperature, followed by acidification at an elevated temperature.
  • a diester of formula (14) ##STR15## where Alk is a C 1-4 alkyl group, e.g. an ethyl group, with a base, e.g. sodium hydroxide, in a solvent, e.g. dioxane, at an elevated temperature, e.g. the reflux temperature, followed by acidification at an elevated temperature.
  • Diesters of formula (14) may be prepared by reacting a diester of formula (15) ##STR16## with an organometallic reagent, such as a Grignard reagent using the conditions described above for the preparation of alcohols of formula (12) (where R is a hydroxy group).
  • organometallic reagent such as a Grignard reagent
  • a compound of formula (12) may be prepared by alkylation of a compound of formula (16): ##STR17## using a reagent R 2 L, where L is a leaving group.
  • Leaving groups represented by L include halogen atoms such as iodine or chlorine or bromine atoms or sulphonyloxy groups such as arylsulphonyloxy groups, e.g. p-toluenesulphonyloxy.
  • the alkylation reaction may be carried out in the presence of a base, e.g. an inorganic base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium-t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide or an ether, e.g. a cyclic ether such as tetrahydrofuran, at ambient temperature or above e.g. around 40° C. to 50° C.
  • a base e.g. an inorganic base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium-t-butoxide, or a hydride, e.g. sodium hydride
  • a dipolar aprotic solvent such as an amide,
  • Intermediates of formula (16) may be obtained from the corresponding protected compound of formula (17): ##STR18## wherein X 1 is a protected hydroxy, thio or amino group using conventional procedures [see Green, T. W. ibid].
  • X 1 is a protected hydroxy, thio or amino group
  • the required hydroxyl group may be obtained by treatment of the protected intermediate with tetrabutylammonium fluoride.
  • the protected intermediate of formula (16) may be prepared in an analogous manner to the compounds of formula (1) using the reactions described herein and appropriately protected intermediates.
  • Compounds of formula (15) may be prepared by condensing an aldehyde of formula (7) with a malonate, e.g. diethylmalonate, if necessary in the presence of catalysts, e.g. piperidine and acetic acid, in an inert solvent, e.g. toluene, at elevated temperature, e.g. the reflux temperature.
  • a malonate e.g. diethylmalonate
  • catalysts e.g. piperidine and acetic acid
  • an inert solvent e.g. toluene
  • Compounds of formula (1) may also be prepared by interconversion of other compounds of formula (1).
  • a group represented by R 3 or R 4 in compounds of formula (1) may be substituted in the aryl or heteroaryl portions by any of the groups R 7 by an appropriate substitution reaction using the corresponding unsubstituted compound of formula (1) and a R 7 containing nucleophile or electrophile.
  • a compound of formula (1) wherein the aryl or heteroaryl group in R 3 or R 4 contains a --CH 2 NH 2 substituent may be prepared by reduction of a corresponding compound wherein R 5 contains a nitrile group, using for example a complex metal hydride such as lithium aluminium hydride in a solvent such as an ether e.g. diethylether.
  • a compound of formula (1) wherein the aryl or heteroaryl group in R 3 and/or R 4 contains an alkanoylamino or alkanoylaminoalkyl substituent may be prepared by acylation of a corresponding compound wherein R 3 and/or R 4 contains a --NH 2 or alkylamino group by reaction with an acyl halide in the presence of a base, such as a tertiary amine e.g. triethylamine in a solvent such as dichloromethane.
  • a base such as a tertiary amine e.g. triethylamine in a solvent such as dichloromethane.
  • compounds of formula (1) wherein R 3 and/or R 4 is substituted by an ester [CO 2 Alk 2 ], e.g. an ethanoate may be prepared by esterification of a corresponding compound wherein R 3 and/or R 4 contains a carboxylic acid, using an acid halide, such as an acid chloride, e.g. acetyl chloride, in an alcohol, such as ethanol, at an elevated temperature, such as the reflux temperature.
  • an acid halide such as an acid chloride, e.g. acetyl chloride
  • Compounds of formula (1) wherein R 3 and/or R 4 is substituted by a carboxylic acid may be prepared from the corresponding compound wherein R 3 and/or R 4 contains a formyl group, by oxidation with an oxidising agent, e.g. potassium permanganate, in a solvent, such as an alcohol, e.g. tert-butanol, at ambient temperature.
  • an oxidising agent e.g. potassium permanganate
  • compounds of formula (1) wherein R 3 and/or R 4 is substituted by an aminoalkyl group, such as dimethylaminomethyl may be prepared by reductive amination of a corresponding compound wherein R 3 and/or R 4 contains a formyl group, using an amine, e.g. dimethylamine, in the presence of a reducing agent, e.g. sodium cyanborohydride, if necessary in the presence of a catalyst, e.g. ethanolic HCl, in a solvent, such as an alcohol, e.g. methanol, at ambient temperature.
  • a reducing agent e.g. sodium cyanborohydride
  • a catalyst e.g. ethanolic HCl
  • solvent such as an alcohol, e.g. methanol
  • a compound of formula (1) wherein R 3 and/or R 4 is substituted by a formyl group may be reduced to the corresponding alcohol, e.g. where R 3 and/or R 4 contains a hydroxymethyl group, using a reducing agent, e.g. sodium borohydride, in a solvent, such as an alcohol, e.g. ethanol, at a temperature from around 20° C. to ambient temperature.
  • a reducing agent e.g. sodium borohydride
  • a solvent such as an alcohol, e.g. ethanol
  • the resulting alcohol may then be converted to the corresponding alkoxy derivative, e.g. methoxymethyl, by reaction with an alkyl halide or alkyl sulphonate using the methods and reagents described above for the alkylation of intermediates of formula (18).
  • compounds of formula (1) wherein R 3 and/or R 4 contains a carboxamido (--CONHR 11 ) or an aminocarbonyl (--NHCOR 11 ) group may be prepared by reaction of the corresponding compound wherein R 3 and/or R 4 contains a --CO 2 H or a --NH 2 group respectively by reaction with a carbamate, such as isobutyl chloroformate or ethyl chloroformate, in the presence of a base, such as an amine, e.g. triethylamine or N-methylmorpholine, in a solvent, such as dichloromethane, or a mixture of solvents, e.g. tetrahydrofuran and dimethylformamide, at a temperature from around -20° C. to room temperature.
  • a carbamate such as isobutyl chloroformate or ethyl chloroformate
  • a base such as an amine, e.g. triethylamine or N-methylmorpho
  • N-oxides of compounds of formula (1) may be prepared by oxidation of the corresponding nitrogen base using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70° C. to 80° C., or alternatively by reaction with a peracid such as peracetic acid in a solvent, e.g. dichloromethane, at ambient temperature.
  • an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid
  • an elevated temperature for example around 70° C. to 80° C.
  • a peracid such as peracetic acid in a solvent, e.g. dichloromethane
  • Salts of compounds of formula (1) may be prepared by reaction of a compound of formula (1) with an appropriate acid or base in a suitable solvent e.g. an organic solvent such as an ether using conventional procedures.
  • a suitable solvent e.g. an organic solvent such as an ether
  • Phenyllithium (1.5M in ether-cyclohexane, 33.5 ml, 50 mmol) was added dropwise to a solution of Intermediate 1 (10.0 g, 45.4 mmol) in THF (50 ml) at about -55° C.
  • the reaction mixture was allowed to warm to RT overnight then diluted with water (100 ml) and extracted with Et 2 O (3 ⁇ 50 ml).
  • the organic extract was washed with aqueous HCl (1%, 70 ml), brine (100 ml), then dried (MgSO 4 ), and concentrated in vacuo to afford 1-(3-cyclopentyloxy-4-methoxyphenyl)-1-phenylmethanol (13.4 g) as a white solid.
  • n-BuLi (1.45M in hexanes; 19.6 ml, 28.4 mmol) was added dropwise at -70° C. to a solution of Intermediate 4 (7.0 g, 25.8 mmol) in THF (50 ml). After stirring for 0.25 h, a solution of 4-cyanopyridine (3.08 g, 29.7 mmol) in THF (15 ml) was added and maintained at -70° C. for 0.75 h. The reaction mixture was then allowed to warm to -10° C. and quenched with aqueous HCl (10%; 60 ml).
  • n-Buli (1.4M in hexanes; 2.7 ml, 3.7 mmol) was added dropwise at -70° C. to a solution of 4-methylpyridine (0.35 g, 3.72 mmol) in THF (20 ml). After 0.5 h, a solution of Intermediate 2 (1.00 g, 3.38 mmol) in THF (4 ml) was added over 5 min at -70° C., the mixture stirred for 1 h at this temperature then allowed to warm to RT over 2 h. The reaction mixture was partitioned between Et 2 O (50 ml) and water (50 ml) and the organic layer was separated.
  • n-BuLi (1.45M in hexanes; 5.1 ml, 7.41 mmol) was added dropwise at -70° C. to a solution of 4-methylpyridine (0.69 g, 7.41 mmol) in THF (20 ml). After 0.5 h a solution of Intermediate 5 (2.0 g, 6.73 mmol) in THF (10 ml) was added dropwise over 5 min. The reaction mixture was stirred for 0.5 h at -70° C. then at RT for 0.5 h. Water (50 ml) was added and the mixture extracted with EtOAc (3 ⁇ 60 ml). The extract was washed with brine (80 ml), dried (MgSO 4 ), and concentrated in vacuo.
  • n-BuLi (1.6M in hexanes; 6 ml, 12 mmol) was added dropwise at 4° C. to a solution of N,N-diisopropylamine (1.85 ml, 13 mmol) in THF (40 ml). After 0.5 h, 2-methoxy-3-methylpyrazine (1.28 ml, 11 mmol) was added dropwise at -70° C. and the mixture stirred for 2 h at this temperature. A solution of Intermediate 2 (3.26 g, 11 mmol) in THF (20 ml) was added over 10 min at -70° C. and the mixture stirred for a further 1 h and then allowed to warm to RT.
  • reaction mixture was partitioned between CH 2 Cl 2 (75 ml) and saturated NaHCO 3 (100 ml). The organic layer was separated, combined with further CH 2 Cl 2 extracts (2 ⁇ 75 ml), dried (MgSO 4 ) and concentrated in vacuo. The residue was subjected to chromatography (SiO 2 ; CH 2 Cl 2 ) to afford the title compound (2.94 g) as a white foam.
  • n-Butyllithium (1.6M solution in hexane; 16.9 ml, 27 mmol) was added to a stirred solution of furan (1.84 g, 1.96 ml, 27 mmol) in THF (25 ml) at -70° C. After 1 h at -70° C., a solution of Intermediate 1 (4.0 g, 18 mmol) in THF (10 ml) was added over 10 min. The reaction mixture was stirred at -70° C. for 0.75 h, warmed to RT over 0.75 h, then quenched with water (100 ml) and extracted with Et 2 O (3 ⁇ 60 ml).
  • n-Butyllithium (1.6M solution in hexanes; 4.2 ml, 6.64 mmol) was added to a solution of a 4-methylpyridine (0.62 g, 0.65 ml, 6.64 mmol) in THF (25 ml) at -70° C.
  • a solution of the crude ketone (1.9 g, ca. 6.6 mmol) in THF (5 ml) was added, stirred for 1 h at -70° C., then at RT for 0.25 h.
  • the reaction mixture was quenched with water (50 ml) and extracted with EtOAc (3 ⁇ 50 ml).
  • the enzymes were purified to kinetic homogeneity using standard chromatographic techniques.
  • Phosphodiesterase activity was assayed as follows. The reaction was conducted in 150 ⁇ l of standard mixture containing (final concentrations): 50 mM TES-NaOH buffer (pH 7.5), 10 mM MgCl 2 , 0.1 ⁇ M [ 3 H]-cAMP and vehicle or various concentrations of the test compounds. The reaction was initiated by addition of enzyme and conducted at 30° C. for between 5 to 30 min. The reaction was terminated by addition of 50 ⁇ l 2% trifluoroacetic acid containing [ 14 C]-5'AMP for determining recovery of the product.
  • a gene encoding human PDE IV has been cloned from human monocytes (Livi, et al., 1990, Molecular and Cellular Biology, 10, 2678). Using similar procedures we have cloned human PDE IV genes from a number of sources including eosinophils, neutrophils, lymphocytes, monocytes, brain and neuronal tissues. These genes have been transfected into yeast using an inducible vector and various recombinant proteins have been expressed which have the biochemical characteristics of PDE IV (Beavo and Reifsnyder, 1990, TIPS, 11, 150). These recombinant enzymes, particularly the human eosinophil recombinant PDE IV, have been used as the basis of a screen for potent, selective PDE IV inhibitors.
  • Compounds, according to the invention cause a concentration-dependent inhibition of recombinant PDE IV at 0.1-1000 nM with little or no activity against PDE I, II, III or V at concentrations up to 100 ⁇ M.
  • the most potent compounds induced a concentration-dependent elevation of cAMP in neutrophils and/or eosinophils at concentrations of 0.1 nM to 1 ⁇ M.
  • LPS Lipopolysaccharide
  • TNF tumour necrosis factor
  • PBM peripheral blood monocytes
  • the effects of compounds of the invention on guinea-pig isolated tracheal smooth muscle were investigated. Isolated tracheal rings were suspended in organ baths and immersed in oxygenated Krebs' solution. The smooth muscle was contracted with sub-maximal concentrations of histamine or carbachol prior to the addition of increasing concentrations of test compound to the organ baths. The most potent compounds caused a concentration-dependent reversal of both histamine and carbachol-induced contractions at concentrations of 1 nM to 100 ⁇ M. The compounds were generally more potent in reversing histamine-induced tone than carbachol-induced tone.
  • Selective PDE IV inhibitors have advantage over theophylline, therefore, through reduced cardiovascular side effects.
  • the most potent and selective compounds of the invention had no direct effects on the atrial and papillary muscles in vitro at concentrations up to 10 ⁇ M but in combination with PDE III inhibitors, these inhibitors showed an enhancement of chronotropic and inotropic activity, typical of selective type IV inhibitors.
  • Interleukin-5 (IL-5)-induced pleural eosinophilia in the rat is inhibited by compounds of the invention given orally at doses of 0.0001 to 10.0 mg/kg.
  • the most potent compounds cause a dose-dependent reduction in migrating eosinophils with ED 50 s of 0.003 to 0.03 mg/kg p.o.
  • PAR platelet activating factor
  • BAL bronchial alveolar lavages
  • the lungs were also removed for histological examination for inflammatory damage.
  • Administration of compounds of the invention (0.001-10 mg/kg i.p. or p.o.), up to three times during the 48 h following antigen challenge, lead to a significant reduction in the eosinophilia and the accumulation of other inflammatory leukocytes. There was also less inflammatory damage in the lungs of animals treated with compounds of the invention.
  • Compounds of the invention are free from adverse effects following repeated overdosage to rats or dogs. For example, oral administration of 125 mg/kg/day of active compounds to rats for 30 days is not associated with adverse toxicity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds of general formula (1) ##STR1## are described wherein Y is a halogen atom or a group --OR1, wherein R1 is an optionally substituted alkyl group; X is --O--, --S-- or --N(R6)--, where R6 is a hydrogen atom or an alkyl group; R2 is an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group; R3 and R4, which may be the same or different, is each a group --(CH2)n Ar, where Ar is a monocyclic or bicyclic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms and n is zero or an integer 1, 2 or 3; R5 is a hydrogen atom or an optionally substituted alkyl group; and the salts, solvates, hydrates and N-oxides. Compounds according to the invention are potent, selective and orally active PDE IV inhibitors and are useful in the prophylaxis and treatment of asthma.

Description

This is a continuation of U.S. application Ser. No. 08/172,047, filed Dec. 22, 1993, abandoned.
This invention relates to a novel series of styryl derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their use in medicine.
Many hormones and neurotransmitters modulate tissue function by elevating intra-cellular levels of adenosine 3', 5'-cyclic monophosphate (cAMP). The cellular levels of cAMP are regulated by mechanisms which control synthesis and breakdown. The synthesis of cAMP is controlled by adenylyl cyclase which may be directly activated by agents such as forskolin or indirectly activated by the binding of specific agonists to cell surface receptors which are coupled to adenylyl cyclase. The breakdown of cAMP is controlled by a family of phosphodiesterase (PDE) isoenzymes, which also control the breakdown of guanosine 3',5'-cyclic monophosphate (cGMP). To date, seven members of the family have been described (PDE I-VII) the distribution of which varies from tissue to tissue. This suggests that specific inhibitors of PDE isoenzymes could achieve differential elevation of cAMP in different tissues, [for reviews of PDE distribution, structure, function and regulation, see Beavo & Reifsnyder (1990) TIPS, 11:150-155 and Nicholson et al (1991) TIPS, 12: 19-27].
There is clear evidence that elevation of cAMP in inflammatory leukocytes leads to inhibition of their activation. Furthermore, elevation of cAMP in airway smooth muscle has a spasmolytic effect. In these tissues, PDE IV plays a major role in the hydrolysis of cAMP. It can be expected, therefore, that selective inhibitors of PDE IV would have therapeutic effects in inflammatory diseases such as asthma, by achieving both antiinflammatory and bronchodilator effects.
The design of PDE IV inhibitors has met with limited success to date, in that many of the potential PDE IV inhibitors which have been synthesised have lacked potency and/or have been capable of inhibiting more than one type of PDE isoenzyme in a non-selective manner. Lack of a selective action has been a particular problem given the widespread role of cAMP in vivo and what is needed are potent selective PDE IV inhibitors with an inhibitory action against PDE IV and little or no action against other PDE isoenzymes.
We have now found a novel series of styryl derivatives, members of which compared to known structurally similar compounds are potent inhibitors of PDE IV at concentrations at which they have little or no inhibitory action on other PDE isoenzymes. These compounds inhibit the isolated PDE IV enzyme and also elevate cAMP in isolated leukocytes. Certain compounds prevent inflammation in the lungs induced by carrageenan, platelet-activating factor (PAF), interleukin-5 (IL-5) or antigen challenge. These compounds also suppress the hyperresponsiveness of airway smooth muscle seen in inflamed lungs. Advantageously, compounds according to the invention have good oral activity and at orally effective doses exhibit little or none of the side-effects associated with known PDE IV inhibitors, such as rolipram. The compounds of the invention are therefore of use in medicine, especially in the prophylaxis and treatment of asthma.
Thus according to one aspect of the invention, we provide a compound of formula (1) ##STR2## wherein Y is a halogen atom or a group --OR1, where R1 is an optionally substituted alkyl group;
X is --O--, --S-- or --N(R6)--, where R6 is a hydrogen atom or an alkyl group.
R2 is an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group;
R3 and R4, which may be the same or different, is each a group --(CH2)n Ar, where Ar is a monocyclic or bicylic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms and n is zero or an integer 1, 2 or 3;
R5 is a hydrogen atom or an optionally substituted alkyl group; and the salts, solvates, hydrates and N-oxides thereof.
The compounds of formula (1) exist as geometrical isomers and the invention extends to all such individual isomers and mixtures thereof. Formula (1) and the formulae hereinafter should be understood to include all individual isomers and mixtures thereof, unless stated otherwise, and even though only one isomer may be depicted.
In the compounds of formula (1), when Y is a halogen atom it may be for example a fluorine, chlorine, bromine or iodine atom.
When Y in the compounds of formula (1) is a group --OR1, R1 may be, for example, an optionally substituted straight or branched alkyl group, for example, an optionally substituted C1-6 alkyl group, such as a methyl, ethyl, n-propyl, or i-propyl, group. Optional substitutents which may be present on R1 groups include one or more halogen atoms, e.g. fluorine, or chlorine atoms. Particular substituted alkyl groups include for example --CH2 F, --CH2 Cl, --CHF2, --CHCl2, --CF3 or --CCl3 groups.
Alkyl groups represented by R2 or R5 in the compounds of formula (1) include optionally substituted straight or branched C1-6 alkyl groups, e.g. C1-3 alkyl groups such as methyl or ethyl groups. Optional substituents on these groups include one, two or three substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or hydroxyl or C1-6 alkoxy e.g. C1-3 alkoxy such as methoxy or ethoxy groups.
Alkenyl groups represented by R2 in the compounds of formula (1) include optionally substituted straight or branched C2-6 alkenyl groups such as ethenyl, propen-1-yl and 2-methylpropen-1-yl. Optional substituents include those described above in relation to the groups R2 and R5.
When R2 in the compounds of formula (1) is an optionally substituted cycloalkyl or cycloalkenyl group it may be for example a C3-8 cycloalkyl group such as a cyclobutyl, cyclopentyl or cyclohexyl group or a C3-8 cycloalkenyl group containing for example one or two double bonds such as 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2,4-cyclopentadien-1-yl, 2-cyclohexen-1-yl, 3-cyclohexen-1-yl, 2,4-cyclohexadien-1-yl or 3,5-cyclohexadien-1-yl group, each cycloalkyl or cycloalkenyl group being optionally substituted by one, two or three substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, straight or branched C1-6 alkyl e.g. C1-3 alkyl such as methyl or ethyl, hydroxyl or C1-6 alkoxy e.g. C1-3 alkoxy such as methoxy or ethoxy groups.
Alkyl groups represented by R6 in compounds of formula (1) include straight or branched C1-6 alkyl groups, e.g. C1-3 alkyl groups such as methyl or ethyl groups.
In the compounds of formula (1) the groups R3 and/or R4 may each independently be a group --Ar, --CH2 Ar, --(CH2)2 Ar or --(CH2)3 Ar.
Monocyclic or bicyclic aryl groups represented by the group Ar in compounds of formula (1) include for example C6-12 optionally substituted aryl groups, for example optionally substituted phenyl, 1- or 2-naphthyl, indenyl or isoindenyl groups.
When the monocyclic or bicyclic aryl group Ar contains one or more heteroatoms it may be for example a C1-9 optionally substituted heteroaryl group containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. In general, Ar heteroaryl groups may be for example monocyclic or bicyclic heteroaryl groups. Monocyclic heteroaryl groups include for example five- or six-membered heteroaryl groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms.
Examples of heteroaryl groups represented by Ar include pyrrolyl, furyl, thienyl, imidazolyl, N-methylimidazolyl, N-ethylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolyl, isoindolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolinyl and 5,6,7,8-tetrahydroisoquinolinyl.
The heteroaryl group represented by Ar may be attached to the remainder of the molecule of formula (1) through any ring carbon or heteroatom as appropriate. Thus, for example, when the group Ar is a pyridyl group it may be a 2-pyridyl, 3-pyridyl or 4-pyridyl group. When it is a thienyl group it may be a 2-thienyl or 3-thienyl group, and, similarly, when it is a furyl group it may be a 2-furyl or 3-furyl group.
When in compounds of formula (1) the Ar group is a nitrogen-containing heterocycle it may be possible to form quaternary salts, for example N-alkyl quaternary salts and the invention is to be understood to extend to such salts. Thus for example when the group Ar is a pyridyl group, pyridinium salts may be formed, for example N-alkylpyridinium salts such as N-methylpyridinium.
The aryl or heteroaryl groups represented by Ar in compounds of formula (1) may each optionally be substituted by one, two, three or more substituents [R7 ]. The substituent R7 may be selected from an atom or group R8 or --Alk1 (R8)m wherein R8 is a halogen atom, or an amino (--NH2), substituted amino, nitro, cyano, hydroxyl (--OH), substituted hydroxyl, cycloalkoxy, formyl [HC(O)--], carboxyl (--CO2 H), esterified carboxyl, thiol (--SH), substituted thiol, --C(O)Alk1, --SO3 H, --SO2 Alk1, --SO2 NH2 13 SO2 NHAlk1, --SO2 N[Alk1 ]2, --CONH2, --CONHAlk1, C--ON[Alk1 ]2, --NHSO2 H, --NHSO2 Alk1, --N[SO2 Alk1 ]2, --NHSO2 NH2, --NHSO2 NHAlk1, --NHSO2 N[Alk1 ]2, --NHC(O)Alk1, or --NHC(O)OAlk1 group; Alk1 is a straight or branched C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene chain optionally interrupted by one, two, or three --O--, or --S-- atoms or --S(O)p--, [where p is an integer 1 or 2] or --N(R6)-- groups; and m is zero or an integer 1, 2 or 3.
When in the group --Alk1 (R8)m m is an integer 1, 2 or 3, it is to be understood that the substituent or substituents R8 may be present on any suitable carbon atom in --Alk1. Where more than one R8 substitutent is present these may be the same or different and may be present on the same or different carbon atom in Alk1. Clearly, when m is zero and no substituent R8 is present or when Alk1 forms part of a group such as --SO2 Alk1 the alkylene, alkenylene or alkynylene chain represented by Alk1 becomes an alkyl, alkenyl or alkynyl group.
When R8 is a substituted amino group it may be a group --NH[Alk1 (R8a)m ] [where Alk1 and m are as defined above and R8a is as defined above for R8 but is not a substituted amino, a substituted hydroxyl or a substituted thiol group] or a group --N[Alk1 (R8a)m ]2 wherein each --Alk1 (R8a)m group is the same or different.
When R8 is a halogen atom it may be for example a fluorine, chlorine, bromine, or iodine atom.
When R8 is a cycloalkoxy group it may be for example a C5-7 cycloalkoxy group such as a cyclopentyloxy or cyclohexyloxy group.
When R8 is a substituted hydroxyl or substituted thiol group it may be a group --OAlk1 (R8a)m or --SAlk1 (R8a)m respectively, where Alk1, R8a and m are as just defined.
Esterified carboxyl groups represented by the group R8 include groups of formula --CO2 Alk2 wherein Alk2 is a straight or branched, optionally substituted C1-8 alkyl group such as a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl group; a C6-12 arylC1-8 alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; a C6-12 aryl group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a C6-12 aryloxyC1-8 alkyl group such as an optionally substituted phenyloxymethyl, phenyloxyethyl, 1-naphthyloxymethyl, or 2-naphthyloxymethyl group; an optionally substituted C1-8 alkanoyloxyC1-8 alkyl group, such as a pivaloyloxymethyl, propionyloxyethyl or propionyloxypropyl group; or a C6-12 aroyloxyC1-8 alkyl group such as an optionally substituted benzoyloxyethyl or benzoyloxypropyl group. Optional substituents present on the Alk2 group include R7 substituents described above.
When Alk1 is present in or as a substituent R7 it may be for example a methylene, ethylene, n-propylene, i-propylene, n-butylene, i-butylene, s-butylene, t-butylene, ethenylene, 2-propenylene, 2-butenylene, 3-butenylene, ethynylene, 2-propynylene, 2-butynylene or 3-butynylene chain, optionally interrupted by one, two, or three --O-- or --S--, atoms or --S(O)--, --S(O)2 -- or --N(R6)-- groups.
Particularly useful atoms or groups represented by R7 include fluorine, chlorine, bromine or iodine atoms, or C1-6 alkyl, e.g. methyl or ethyl, 6 alkylamino, e.g. methylamino or ethylamino, C1-6 hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, C1-6 alkylthiol e.g. methylthiol or ethylthiol, C1-6 alkoxy, e.g. methoxy or ethoxy, C5-7 cycloalkoxy, e.g. cyclopentyloxy, haloC1-6 alkyl, e.g. trifluoromethyl, C1-6 alkylamino, e.g. methylamino or ethylamino, amino (--NH2), aminoC1-6 alkyl, e.g. aminomethyl or aminoethyl, C1-6 dialkylamino, e.g. dimethylamino or diethylamino, nitro, cyano, hydroxyl (--OH), formyl [HC(O)--], carboxyl (--CO2 H), --CO2 Alk2 [where Alk2 is as defined above], C1-6 alkanoyl e.g. acetyl, thiol (--SH), thioC 1-6 alkyl, e.g. thiomethyl or thioethyl, sulphonyl (--SO3 H), C1-6 alkylsulphonyl, e.g. methylsulphonyl, aminosulphonyl (--SO2 NH2), C1-6 alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C1-6 dialkylaminosulphonyl, e.g. di-methylaminosulphonyl or diethylaminosulphonyl, carboxamido (--CONH2), C1-6 alkylaminocarbonyl, e.g. methylaminocarbonyl or ethylaminocarbonyl, C1-6 dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, sulphonylamino (--NHSO2 H), C1-6 alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, C1-6 dialkylsulphonylamino, e.g. dimethylsuiphonylamino or diethylsulphonylamino, aminosulphonylamino (--NHSO2 NH2), C1-6 alkylaminosulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino, C1-6 dialkylaminosulphonylamino, e.g. dimethylaminosulphonylamino or diethylaminosulphonylamino, C1-6 alkanoylamino, e.g. acetylamino, C1-6 alkanoylamino C1-6 alkyl, e.g. acetylaminomethyl or C1-6 alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylamino or t-butoxycarbonylamino groups.
Where desired, two R7 substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C2-6 alkylenedioxy group such as ethylenedioxy.
It will be appreciated that where two or more R7 substituents are present, these need not necessarily be the same atoms and/or groups. The R7 substituents may be present at any ring carbon atom away from that attached to the rest of the molecule of formula (1). Thus, for example, in phenyl groups represented by Ar any substituent may be present at the 2-, 3-, 4-, 5- or 6-positions relative to the ring carbon atom attached to the remainder of the molecule.
In the compounds of formula (1), when an ester group is present, for example a group --CO2 Alk2 this may advantageously be a metabolically labile ester.
The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.
Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, or isethionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or napsylates, phosphates, sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.
Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.
Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.
In the compounds of formula (1), the group Y is preferably an --OR1 group, especially where R1 is an optionally substituted ethyl group or, especially, an optionally substituted methyl group. Especially useful substitutents which may be present on R1 groups include one, two or three fluorine or chlorine atoms.
The group X in compounds of formula (1) is preferably --O--.
A particularly useful group of compounds of formula (1) has the formula (2): ##STR3## where R2 is an optionally substituted cycloalkyl group; R3 , R4, and R5 are as defined for formula (1); and the salts, solvates, hydrates and N-oxides thereof.
In the compounds of formulae (1) or (2) R2 is preferably an optionally substituted cyclopentyl group. In particular, R2 is a cyclopentyl group.
In compounds of formulae (1) or (2) the group R5 is preferably a hydrogen atom.
The group R3 and R4 in compounds of formulae (1) or (2) is each preferably a --CH2 Ar group, or, especially an --Ar group.
Particularly useful R3 or R4 groups in compounds of formulae (1) or (2) include those R3 or R4 groups in which Ar is a monocyclic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur, or, in particular, nitrogen atoms, and optionally substituted by one, two or more R7 substituents. In these compounds, when the group represented by Ar is a heteroaryl group it is preferably a nitrogen-containing monocyclic heteroaryl group, especially a six-membered nitrogen-containing heteroaryl group. Thus, in one preferred example, the groups R4 and R5 may each be a six-membered nitrogen-containing heteroaryl group. In another preferred example R4 may be a monocyclic aryl group and R5 may be a six-membered nitrogen-containing heteroaryl group. In these examples, the six-membered nitrogen-containing heteroaryl group may be an optionally substituted pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl group. Particular examples include optionally substituted 2-pyridyl, 3-pyridyl or, especially, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl or 3-pyrazinyl. The monocyclic aryl group may be a phenyl group or a substituted phenyl group.
One particularly useful group of compounds of formulae (1) or (2) is that wherein R3 and R4 is each a pyridyl or, especially, a monosubstituted pyridyl, or preferably a disubstituted pyridyl group, or R3 is a phenyl or substituted phenyl group and R4 is a pyridyl or, especially a monosubstituted pyridyl, or preferably a disubstituted pyridyl group.
In this particular group of compounds and also in general in compounds of formulae (1) or (2), when R3 and/or R4 is a substituted phenyl group it may be for example a mono-, di- or trisubstituted phenyl group in which the substituent is an atom or group R7 as defined above. When the R3 and/or R4 group is a monosubstituted phenyl group the substituent may be in the 2-, or preferably 3-, or especially 4-position relative to the ring carbon atom attached to the remainder of the molecule.
When in compounds of formulae (1) or (2) R3 and/or R4 is a substituted pyridyl group it may be for example a mono-or disubstituted pyridyl group, such as a mono- or disubstituted 2-pyridyl, 3-pyridyl or especially 4-pyridyl group substituted by one or two atoms or groups R7 as defined above, in particular one or two halogen atoms such as fluorine or chlorine atoms, or methyl, methoxy, hydroxyl or nitro groups. Particularly useful pyridyl groups of these types are 3-monosubstituted-4-pyridyl or 3,5-disubstituted-4-pyridyl, or 2- or 4-monosubstituted-3-pyridyl or 2,4-disubstituted-3-pyridyl groups.
A particularly useful group of compounds according to the invention has the formula (2) wherein R5 is a hydrogen atom and R3 and R4 are as defined for formula (1); and the salts, solvates, hydrates and N-oxides thereof. Compounds of this type in which R3 is an optionally substituted phenyl, or pyridyl in particular 4-pyridyl, group and R4 is a pyridyl especially a 4-pyridyl group are particularly preferred.
Particularly useful compounds according to the invention are the (E) and (Z) isomers of
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(2-furanyl)ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(2thienyl)ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]-3-methylimidazole;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]pyridine;
4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-fluorophenylethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-trifluoromethylphenyl)ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(2-methoxyphenylethenyl)]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-( 4-methoxyphenyl)ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-methylphenyl) ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(3-methylphenyl)ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(3-cyclopentyloxy-4-methoxyphenyl)ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]-3,5-dichloropyridine;
2-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]pyridine;
4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl) ethenyl]aniline;
4-[1-(3-Cyclopenxyloxy-4-methoxyphenyl0-2-(4-pyridyl)ethenyl]benzoic acid;
Ethyl N-{4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl) ethenyl]phenyl}carbamate;
N-{4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2(4-pyridyl)ethenyl]phenyl}N'-ethylurea;
N-{4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)]-2-(4-pyridyl)ethenyl}phenylacetamide;
3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]pyridine;
4-[2-2(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]pyrimidine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-hydroxymethylphenyl)ethenyl]pyridine;
4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethenyl]benzamide;
Ethyl-4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-phenylethenyl]benzoate;
N-{4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethenyl]phenyl}methanesulphonamide; or
each enantiomer thereof; and the salts, solvates, hydrates and N-oxides thereof.
Compounds according to the invention are selective and potent inhibitors of PDE IV. The ability of the compounds to act in this way may be simply determined by the tests described in the Examples hereinafter.
The compounds according to the invention are thus of particular use in the prophylaxis and treatment of human diseases where an unwanted inflammatory response or muscular spasm is present and where the elevation of cAMP levels may be expected to prevent or alleviate the inflammation and relax muscles.
Particular uses to which the compounds of the invention may be put include the prophylaxis and treatment of asthma, especially inflamed lung associated with asthma, or in the treatment of inflammatory airway disease, chronic bronchitis, eosinophilic granuloma, psoriasis and other benign and malignant proliferative skin diseases, endotoxic shock, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, atopic dermatitis, urticaria, allergic rhinitis, adult respiratory distress syndrome, diabetes insipidus, allergic conjunctivitis and vernal conjunctivitis.
Compounds according to the invention may also elevate cAMP in lymphocytes and thereby suppress unwanted lymphocyte activation in immune-based diseases such as rheumatoid arthritis, transplant rejection and graft versus host disease.
For the prophylaxis or treatment of disease the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.
Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral or nasal administration, or a form suitable for administration by inhalation or insufflation.
For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.
The compounds of formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular injection.
For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispense device may be accompanied by instructions for administration.
The quantity of a compound of the invention required for the prophylaxis or treatment of a particular inflammatory condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100 ng/kg to 100 mg/kg, e.g. around 0.01 mg/kg to 40 mg/kg body weight for oral or buccal administration, from around 10 ng/kg to 50 mg/kg body weight for parenteral administration, and around 0.05 mg to around 1000 mg for nasal administration or administration by inhalation or insufflation.
The compounds according to the invention may be prepared by the following processes. The symbols Y, R2, R3, R4, R5, and X1, when used in the formulae below are to be understood to represent those groups described above in relation to formula (1) unless otherwise indicated. In the reactions described below it may be necessary to protect reactive functional groups, for example hydroxy, amino or thiol groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice [see, for example, Green, T. W. in "Protective Groups in Organic Synthesis" John Wiley and Sons, 1981.] It may be that deprotection will form the last step in the synthesis of compounds of formula (1). Thus, for example, compounds of formula (1), wherein R3 and/or R4 contains a carboxylic group may be prepared by deprotecting the corresponding compound wherein R3 and/or R4 contains a protected carboxyl group, such as an oxazolinyl e.g. 4,4-dimethyl-2-oxazolinyl, in the presence of a base, e.g. sodium hydroxide, in an acid solvent, e.g. aqueous hydrochloric acid, at an elevated temperature, e.g. the reflux temperature.
Thus according to a further aspect of the invention, a compound of formula (1) may be prepared by dehydration of an alcohol of formula (3): ##STR4## using an acid or base-catalysed elimination.
Suitable acids include for example phosphoric or sulphonic acids, e.g. 4-toluenesulphonic acid. The reaction may be performed in an inert organic solvent, for example a hydrocarbon such as toluene, at an elevated temperature, for example the reflux temperature. Base catalysed elimination may be performed using for example trifluoroacetic anhydride in the presence of an organic base such as triethylamine at a low temperature e.g. from around 0° C. to ambient temperature, in a solvent such as dichloromethane or tetrahydroduran.
In certain instances, the reaction conditions used may also cleave the group R2 in the starting material of formula (4) to yield a compound of formula (1) where R2 is a hydrogen atom. Such compounds may be converted to the required compound of formula (3) by a further process according to the invention using a halide R2 Hal (where Hal is a halogen atom such as a bromine or chlorine atom) where necessary in the presence of a base such as caesium or potassium carbonate or an alkoxide such as potassium t-butoxide, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide at ambient temperature or above e.g. around 40° C. to 50° C.
Intermediates of formula (3) may be prepared by reaction of a ketone of formula (4): ##STR5## with an organometallic reagent R4 R5 CHZ where Z is a metal atom.
Metal atoms represented by Z include, for example, a lithium atom.
The reaction may be performed in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at a low temperature, e.g. around -70° C. to ambient temperature. This reaction is particularly suitable for the preparation of compounds of formula (1) wherein R4 is an electron deficient group such as a 2- or 4-pyridyl group.
Reagents R4 R5 CHZ are either known compounds or may be prepared, preferably in situ during the above process, by reaction of a compound AlkCH2 Z [where Alk is an alkyl group such as a n-propyl group] with a compound R4 R5 CH2 where necessary in the presence of a base such as an amine e.g. diisopropylamine using the above-mentioned conditions.
Ketones of formula (4) may be prepared by oxidation of a corresponding alcohol of formula (5): ##STR6## using an oxidising agent such as manganese dioxide in a solvent such as dichloromethane at ambient temperature.
Alternatively, ketones of formula (4) may be prepared by reaction of a halide of formula (6): ##STR7## [where Hal is a halogen atom such as a bromine or chlorine atom] by halogen-metal exchange with a base such as n-butyllithium, followed by reaction with a nitrile R3 CN, an acid chloride R3 COCl or an ester R3 CO2 Alk (where Alk is an alkyl group, e.g. a methyl group) in a solvent such as tetrahydrofuran, at a low temperature, e.g. around -70° C., and subsequent treatment with an acid such as hydrochloric acid at e.g. -20° C. to ambient temperature.
Alcohols of formula (5) may be prepared by reaction of an aldehyde of formula (7): ##STR8## with organometallic compound, such as an organolithium compound R3 Li, or a Grignard reagent R3 MgBr, in a solvent, such as tetrahydrofuran, at a low temperature, e.g. around -55° C. to 0° C.
Aldehydes of formula (7) may be prepared by alkylation of a corresponding compound of formula (8): ##STR9## using a compound R2 Hal [where Hal is as previously defined] using the reagents and conditions described herein above for the alkylation of intermediates of formula 4.
Intermediates of formula (8) are either known compounds or may be prepared from known starting materials by methods analogous to those used for the preparation of the known compounds.
Halides of formula (6) may be prepared by alkylation of a compound of formula (9): ##STR10## using the reagents and conditions discussed above in relation to the alkylation of aldehydes of formula (8).
Halides of formula (9) where X is --O-- may be prepared by oxidation of an aldehyde of formula (10): ##STR11## using an oxidising agent such as 3-chloroperoxybenzoic acid in a halogenated hydrocarbon such as chloroform at a temperature from around 0° C. to room temperature.
Aldehydes of formula (8) and halides of formula (10) where X is --S-- or --N(R6)-- are either known compounds or may be prepared from known starting materials by methods analogous to those used for the preparation of the known compounds.
In yet another aspect of the invention, compounds of formula (1) may be obtained by coupling a compound of formula (11) ##STR12## in a Heck reaction with an organopalladium compound derived from a compound R4 Hal [where Hal is a halogen atom, such as a bromine atom] and a palladium salt, such as palladium acetate, in the presence of a phosphine such as tri-o-tolylphosphine and a base such as triethylamine at an elevated temperature and pressure.
Intermediate alkenes of formula (11) may be obtained by reaction of a corresponding ketone of formula (4) (described herein above) using a Wittig reaction employing a phosphonium salt such as methyltriphenylphosphonium bromide in the presence of a base such as n-butyllithium and in inert solvent such as tetrhydrofuran at, for example, 0° C. to ambient temperature.
In a further process according to the invention a compound of formula (1) may be prepared by dehydrogenation of a compound of formula (12): ##STR13## where R is ahydrogen atom, using a dehydrogenating agent.
Suitable dehydrogenation reagents include for example quinones such as 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, in a solvent, e.g. dioxane, at an elevated temperature, e.g. the reflux temperature.
Compounds of formula (12) may be prepared by cyclisation of a compound of formula (13) ##STR14## where R is a carboxylic acid [--CO2 H] group or a reactive derivative thereof; or a nitrile [--CN] or an imine salt with a bifunctional reagent W1 R4a W2 and, where necessary, a compound R4b W3 [where W1, W2 and W3, which may be the same or different, is each a reactive functional group or a protected derivative thereof; and R4a and R4b are components of the heteroaryl group R4 such that when added together with W1, W2 and W3 to the group R in compounds of formula (15) the resulting group --RW1 R4a W2 or --RW1 R4a W2 R4b W3 constitutes the heteroaryl group R4 ].
Reactive derivatives of carboxylic acids for use in this reaction include acid halides, (e.g. acid chlorides), amides, including thioamides, or esters, including thioesters. Imine salts include for example salts of formula [e.g. --C(OAlk)═NH2 + A-, where Alk is a C1-4 alkyl group and A- is a counterion e.g. a chloride ion].
in this general reaction the reactive functional groups represented by W1, W2 or W3 may be any suitable carbon, nitrogen, sulphur or oxygen nucleophiles. Particular examples include simple nucleophiles such as carbanions [e.g. generated by the coupling of an alkyl group with an organometallic compound], amino, thiol and hydroxyl groups.
In general, the cyclisation reaction will initially be performed in a solvent, for example an inert solvent such as a halocarbon, e.g. dichloromethane, an ether, e.g. a cyclic ether such as tetrahydrofuran, or a hydrocarbon, e.g. an aromatic hydrocarbon such as toluene, from a low temperature, e.g. around -70° C., to around the reflux temperature, where necessary in the presence of a base or a thiation reagent, e.g. Lawesson's reagent, followed if necessary by heating, to an elevated temperature, e.g. the reflux temperature.
Thus, in one particular example, compounds of formula (12) wherein R4 is a benzothiazolyl, benzoxazolyl or benzimidazolyl group may be prepared by reaction of a compound of formula (13) where R is an acid halide, e.g. acid chloride, with a reagent W1 R4a W2 which is 2-aminothiophenol, 2-hydroxyphenol, or 1,2-diaminobenzene respectively in the presence of a base e.g. an organic amine such as pyridine, in a solvent e.g. a halocarbon such as dichloromethane, from around -70° C. to the reflux temperature.
In another example of the general cyclisation process, a compound of formula (13) where R is an acid halide as described above may be reacted with a compound W1 R4a W2 which is a monoalkylmalonate, e.g. ethyl hydrogen malonate, followed by reaction with a compound R4b W3 which is hydrazine to give a compound of formula (1) wherein R4 is a 5-hydroxypyrazolyl group.
In another variation of the cyclisation process, the halide of formula (13) may be reacted with a compound W1 R4a W2 which is BrMg(CH2)3 [--O(CH2)2 O--] followed by reaction in an acid solution with a compound R4b W3 which is methylamine to yield a compound of formula (1) wherein R4 is a N-methyl pyrrole group.
In a further example of the cyclisation process, the halide of formula (13) may be reacted with a compound W1 R4a W2 which is H2 NNHCSNH2 in an aromatic hydrocarbon such as toluene, at an elevated temperature, e.g. around 150° C., followed by treatment with a base, e.g. an inorganic base such as sodium bicarbonate to give a compound of formula (12) wherein R4 is a 1,2,4-triazolyl-5-thiolate group.
Intermediate compounds of formula (13) are particularly useful and form a further aspect of the invention. Active derivatives of the acids of formula (13) and other compounds of formula (13) where R is a nitrile or an imine salt may be prepared from the corresponding acids [where R is --CO2 H] using conventional procedures for converting carboxylic acids to such compounds, for example as described in the Examples hereinafter.
Acids of formula (13) [where R is --CO2 H] may be prepared by hydrolysing a diester of formula (14) ##STR15## where Alk is a C1-4 alkyl group, e.g. an ethyl group, with a base, e.g. sodium hydroxide, in a solvent, e.g. dioxane, at an elevated temperature, e.g. the reflux temperature, followed by acidification at an elevated temperature.
Diesters of formula (14) may be prepared by reacting a diester of formula (15) ##STR16## with an organometallic reagent, such as a Grignard reagent using the conditions described above for the preparation of alcohols of formula (12) (where R is a hydroxy group).
In another process according to the invention, a compound of formula (12) may be prepared by alkylation of a compound of formula (16): ##STR17## using a reagent R2 L, where L is a leaving group.
Leaving groups represented by L include halogen atoms such as iodine or chlorine or bromine atoms or sulphonyloxy groups such as arylsulphonyloxy groups, e.g. p-toluenesulphonyloxy.
The alkylation reaction may be carried out in the presence of a base, e.g. an inorganic base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium-t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide or an ether, e.g. a cyclic ether such as tetrahydrofuran, at ambient temperature or above e.g. around 40° C. to 50° C.
Intermediates of formula (16) may be obtained from the corresponding protected compound of formula (17): ##STR18## wherein X1 is a protected hydroxy, thio or amino group using conventional procedures [see Green, T. W. ibid]. Thus, for example, where X is a t-butyldimethylsilyloxy group, the required hydroxyl group may be obtained by treatment of the protected intermediate with tetrabutylammonium fluoride. The protected intermediate of formula (16) may be prepared in an analogous manner to the compounds of formula (1) using the reactions described herein and appropriately protected intermediates.
Compounds of formula (15) may be prepared by condensing an aldehyde of formula (7) with a malonate, e.g. diethylmalonate, if necessary in the presence of catalysts, e.g. piperidine and acetic acid, in an inert solvent, e.g. toluene, at elevated temperature, e.g. the reflux temperature.
Compounds of formula (1) may also be prepared by interconversion of other compounds of formula (1). Thus, for example, a group represented by R3 or R4 in compounds of formula (1) may be substituted in the aryl or heteroaryl portions by any of the groups R7 by an appropriate substitution reaction using the corresponding unsubstituted compound of formula (1) and a R7 containing nucleophile or electrophile.
In another example of an interconversion process a compound of formula (1) wherein the aryl or heteroaryl group in R3 or R4 contains a --CH2 NH2 substituent may be prepared by reduction of a corresponding compound wherein R5 contains a nitrile group, using for example a complex metal hydride such as lithium aluminium hydride in a solvent such as an ether e.g. diethylether.
In a further example, a compound of formula (1) wherein the aryl or heteroaryl group in R3 and/or R4 contains an alkanoylamino or alkanoylaminoalkyl substituent may be prepared by acylation of a corresponding compound wherein R3 and/or R4 contains a --NH2 or alkylamino group by reaction with an acyl halide in the presence of a base, such as a tertiary amine e.g. triethylamine in a solvent such as dichloromethane.
In yet another example of an interconversion process, compounds of formula (1) wherein R3 and/or R4 is substituted by an ester [CO2 Alk2 ], e.g. an ethanoate, may be prepared by esterification of a corresponding compound wherein R3 and/or R4 contains a carboxylic acid, using an acid halide, such as an acid chloride, e.g. acetyl chloride, in an alcohol, such as ethanol, at an elevated temperature, such as the reflux temperature.
Compounds of formula (1) wherein R3 and/or R4 is substituted by a carboxylic acid may be prepared from the corresponding compound wherein R3 and/or R4 contains a formyl group, by oxidation with an oxidising agent, e.g. potassium permanganate, in a solvent, such as an alcohol, e.g. tert-butanol, at ambient temperature.
In a further interconversion reaction, compounds of formula (1) wherein R3 and/or R4 is substituted by an aminoalkyl group, such as dimethylaminomethyl, may be prepared by reductive amination of a corresponding compound wherein R3 and/or R4 contains a formyl group, using an amine, e.g. dimethylamine, in the presence of a reducing agent, e.g. sodium cyanborohydride, if necessary in the presence of a catalyst, e.g. ethanolic HCl, in a solvent, such as an alcohol, e.g. methanol, at ambient temperature.
In another example of an interconversion reaction a compound of formula (1) wherein R3 and/or R4 is substituted by a formyl group, may be reduced to the corresponding alcohol, e.g. where R3 and/or R4 contains a hydroxymethyl group, using a reducing agent, e.g. sodium borohydride, in a solvent, such as an alcohol, e.g. ethanol, at a temperature from around 20° C. to ambient temperature. The resulting alcohol may then be converted to the corresponding alkoxy derivative, e.g. methoxymethyl, by reaction with an alkyl halide or alkyl sulphonate using the methods and reagents described above for the alkylation of intermediates of formula (18).
In a further example of an interconversion process compounds of formula (1) wherein R3 and/or R4 contains a carboxamido (--CONHR11) or an aminocarbonyl (--NHCOR11) group may be prepared by reaction of the corresponding compound wherein R3 and/or R4 contains a --CO2 H or a --NH2 group respectively by reaction with a carbamate, such as isobutyl chloroformate or ethyl chloroformate, in the presence of a base, such as an amine, e.g. triethylamine or N-methylmorpholine, in a solvent, such as dichloromethane, or a mixture of solvents, e.g. tetrahydrofuran and dimethylformamide, at a temperature from around -20° C. to room temperature.
N-oxides of compounds of formula (1) may be prepared by oxidation of the corresponding nitrogen base using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70° C. to 80° C., or alternatively by reaction with a peracid such as peracetic acid in a solvent, e.g. dichloromethane, at ambient temperature.
Salts of compounds of formula (1) may be prepared by reaction of a compound of formula (1) with an appropriate acid or base in a suitable solvent e.g. an organic solvent such as an ether using conventional procedures.
The following examples illustrate the invention. The following abbreviations are used: DMF--dimethylformamide; THF--tetrahydrofuran; DME--dimethoxyethane; EtOAc--ethyl acetate; Et2 O--diethylether; Et3 N--triethylamine; CH2 Cl2 --dichloromethane; BuLi--butyllithium; LDA--lithium diisopropylamide; EtOH--ethanol; RT--room temperature.
INTERMEDIATE 1
3-Cyclopentyloxy-4-methoxybenzaldehyde
Cs2 CO3 (214 g, 0.66 mol) was added to a mixture of 3-hydroxy-4-methoxybenzaldehyde (100 g, 0.66 mol) and cyclopentyl bromide (98 g, 0.66 mol) in anhydrous DMF (500 ml). The reaction mixture was stirred at RT for 16 h then treated with a further portion of cyclopentyl bromide (98 g, 0.66 mol) and Cs2 CO3 (214 g, 0.66 mol). After a further 6 h at RT, the mixture was filtered and concentrated in vacuo. The residue was dissolved in CH2 Cl2 (300 ml) and washed with NaOH solution (10%; 2×150 ml). The organic layer was dried (MgSO4), concentrated in vacuo, and distilled (150° C., 10-2 mbar) to afford the title compound (130 g) as a viscous colourless oil. δH (CDCl3) 1.5-2.0 (8H, br m, CH2)4), 3.87 (3H, s, OMe), 4.80 (1H, br m, OCHCH2), 6.90 (1H, d, J 8.7 Hz, ArH ortho to OMe), 7.30-7.45 (2H, m, 2×ArH meta to OMe), and 9.77 (1H, s, ArCHO).
INTERMEDIATE 2
(3-Cyclopentyloxy-4-methoxyphenyl)phenylketone
Phenyllithium (1.5M in ether-cyclohexane, 33.5 ml, 50 mmol) was added dropwise to a solution of Intermediate 1 (10.0 g, 45.4 mmol) in THF (50 ml) at about -55° C. The reaction mixture was allowed to warm to RT overnight then diluted with water (100 ml) and extracted with Et2 O (3×50 ml). The organic extract was washed with aqueous HCl (1%, 70 ml), brine (100 ml), then dried (MgSO4), and concentrated in vacuo to afford 1-(3-cyclopentyloxy-4-methoxyphenyl)-1-phenylmethanol (13.4 g) as a white solid. m.p. 82.5°-83° C.; δH (CDCl3) 1.5-2.0 (8H, br, m, (CH2)4), 2.30 (1H, br, s, OH), 3.77 (3H, s, OMe), 4.68 (1H, br, m, OCHCH2), 5.77 (1H, s, CHOH), 6.75-6.85 (3H, m, ArH ortho to OMe+2×ArH meta to OMe), and 7.15-7.4 (5H, m, C6 H5); m/z 298 (M+ 20%), 230 (50), 151 (30), 125 (100), 124 (33), 105 (38), and 92 (22).
The alcohol (prepared above) (13.4 g, 44.8 mmol) was dissolved in CH2 Cl2 (150 ml) and treated with MnO2 (22 g). The reaction mixture was vigorously stirred at RT for 18 h then treated with a further portion of MnO2 (20 g). More MnO2 (20 g) was added after 10 h and the mixture stirred for 18 h then filtered through Celite® and concentrated in vacuo. The residue was recrystallised from EtOH to afford the title compound (11.27 g; two crops) as a white crystalline solid m.p. 59°-75° C.; δH (CDCl3) 1.5-2.1 (8H, br, m, (CH2)4), 3.88 (3H, s, OMe), 4.80 (1H, br m, OCHCH2), 6.83 (1H, d, J 8.5 Hz, ArH ortho to OMe), and 7.25-7.8 (7H, m, 2×ArH meta to OMe+C6 H5); m/z 296 (M+ 11%), 229 (17), 228 (95), 152 (12), 151 (100), 105 (30), 77 (21), and 41 (10).
INTERMEDIATE 3
5-Bromo-2-methoxyphenol
A solution of 5-bromo-2-methoxybenzaldehyde (100 g, 0.46 mol) in CHCl3 (150 ml) was cooled with an ice bath and 3-chloroperoxybenzoic acid (50-60% purity) (146 g, 0.51 mol) in CHCl3 (1000 ml) added. The reaction mixture was allowed to warm slowly to room temperature and stirred for 72 h. The white solid was filtered off and the filtrate concentrated in vacuo. The residue was dissolved in Et2 O (200 ml) and washed with 1M sodium sulphite solution (2×200 ml) then NaHCO3 [half saturated] (3×200 ml). The ether layer was washed with 10% aqueous NaOH (3×100 ml) and the combined basic extract was acidified with concentrated hydrochloric acid and extracted with Et2 O (3×100 ml). The combined organic extract was dried (MgSO4) and florisil (10 g) filtered and the solvent removed under reduced pressure to give the title compound (90 g) as a pale brown solid.
INTERMEDIATE 4
4-Bromo-2-cyclopentyloxyanisole
Intermediate 3 (90 g)was dissolved in DMF (300 ml), and treated with Cs2 CO3 (158 g, 490 mmol), and cyclopentyl bromide (73 g, 52.5 ml, 490 mmol). After stirring overnight, further CS2 CO3 (35 g, 107 mmol) and cyclopentylbromide (12 ml, 16.7 g, 112 mmol) were added and stirring continued for 2 h. Further portions of cyclopentylbromide (10 ml) and CS2 CO3 were then added (14 g). After stirring for 1 h, the DMF was evaporated in vacuo and the residue diluted with water (200 ml) and extracted with Et2 O (3×100 ml). The combined organic extract was washed with NaOH solution (5%, 2>100 ml), water (100 ml), then dried (MgSO4) and the solvent evaporated in vacuo to give a red oil which was distilled (140° C., 0.3 mbar) to afford the title compound (101 g) as a colourless oil (Found: C, 53.11; H, 5.53. C12 H15 BrO2 requires C, 53.15; H, 5.58%).
INTERMEDIATE 5
(3-Cyclopentyloxy-4-methoxyphenyl)(4-pyridyl)ketone
n-BuLi (1.45M in hexanes; 19.6 ml, 28.4 mmol) was added dropwise at -70° C. to a solution of Intermediate 4 (7.0 g, 25.8 mmol) in THF (50 ml). After stirring for 0.25 h, a solution of 4-cyanopyridine (3.08 g, 29.7 mmol) in THF (15 ml) was added and maintained at -70° C. for 0.75 h. The reaction mixture was then allowed to warm to -10° C. and quenched with aqueous HCl (10%; 60 ml). The mixture was stirred for 0.5 h, basified with aqueous NaOH (10%, 70 ml), and extracted with Et2 O (3×70 ml). The extract was washed with brine (100 ml), dried (MgSO4), and concentrated in vacuo, The residue was subjected to chromatography (SiO2 ; EtOAc/hexane, 4:1) to afford the title compound (6.34 g) as a white powder. δH (CDCl3) 1.5-1.9 (8H, br m, (CH2)4), 3.90 (3H, s, OMe), 4.82 (1H, br m, OCHCH2), 6.84 (1H, d, J 8.4 Hz, ArH ortho to OMe) 7.29 (1H, dd, J 8.4, 2.0 Hz, ArH para to cyclopentyloxy), 7.4-7.55 (3H, m, ArH ortho to cyclopentyloxy+pyridine H3, H5), and 8.73 (2H, dd, J 4.4 Hz, 1.5 Hz, pyridine H2, H6).
INTERMEDIATE 6
(E) and (Z) isomers of 4-[1-(3-Hydroxy-4-methoxyphenyl)-2-(4-pyridyl) ethenyl]pyridine
Intermediate 8 (0.72 g, 1.85 mmol) in toluene (120 ml) containing 4-toluenesulphonic acid (0.88 g, 4.6 mmol) was heated to reflux in a Dean-Stark apparatus for 18 h. The cooled reaction mixture was treated with aqueous NaOH (10%) then taken to pH 7 with concentrated hydrochloric acid. The mixture was extracted with CH2 Cl2 (3×40 ml), the extract washed with saturated NaHCO3 (100 ml), and Na2 CO3 (10%; 2×60 ml), then dried (MgSO4), and concentrated in vacuo to afford the title compound (0.4 g) as a yellow foam; δH (CDCl3) (major isomer) 3.88 (3H, s, OMe), 6.6-6.9 (6H, m, ArH ortho to OMe+2×ArH meta to OMe+C═CH+pyridine H3, H5), 7.08 (2H, dd, J 4.6, 1.6 Hz, pyridine H3, H5), 8.30 (2H, dd, J 4.5, 1.6 Hz, pyridine H2, H6), and 8.51 (2H, dd, J 4.4, 1.6 Hz, pyridine H2, H6), [the minor isomer displays a signal at δ 3.90 (3H, s, OMe)].
INTERMEDIATE 7
a) (±)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-hydroxy-2-phenylethyl]pyridine
n-Buli (1.4M in hexanes; 2.7 ml, 3.7 mmol) was added dropwise at -70° C. to a solution of 4-methylpyridine (0.35 g, 3.72 mmol) in THF (20 ml). After 0.5 h, a solution of Intermediate 2 (1.00 g, 3.38 mmol) in THF (4 ml) was added over 5 min at -70° C., the mixture stirred for 1 h at this temperature then allowed to warm to RT over 2 h. The reaction mixture was partitioned between Et2 O (50 ml) and water (50 ml) and the organic layer was separated. The aqueous layer was further extracted with Et2 O (2×40 ml) and the combined organic extract was dried (MgSO4) and concentrated in vacuo. The residue was subjected to chromatography (SiO2 ; EtOAc-hexane) to afford, first, Intermediate 2 (300 mg) then the title compound (738 mg) as a white solid. m.p. 148°-149° C. (toluene-hexane)(Found: C, 77.32; H, 7.04; N, 3.50. C25 H27 O3 requires C, 77.09; H, 6.99; N, 3.60%); δH (CDCl3) 1.4-1.9 (8H, br, m, (CH2)4), 2.3 (1H, v.br.s, OH exchanges with D2 O), 3.51 (2H, s, CH2 pyridine), 3.78 (3H, s, OMe), 4.60 (1H, br, m, OCHCH2), 6.65-6.9 (5H, m) and 7.15-7.4 (5H, m) (ArH ortho to OMe+2×ArH meta to OMe+C6 H5 +pyridine H3, H5), and 8.22 (2H, dm, J 4.5 Hz, pyridine H2, H6): m/z 389 (M+ 3%), 298 (15), 297 (69), 229 (27), 228 (37), 151 (43), 105 (100), 93 (52), 77 (24), and 41 (14).
The following compounds were prepared in a manner similar to Intermediate 7a.
b) (±)-2-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-hydroxy-2-phenylethyl]pyrazine
From 2-methylpyrazine (1.0 ml, 110 mmol) and Intermediate 2 (3.24 g, 11.0 mmol). Trituration with Et2 O gave the title compound (0.885 g) as a white solid. δH (CDCl3) 1.45-1.9 (8H, br, m, (CH2)4), 3.73 (2H, s, CH2 pyrazine), 3.80 (3H, s, OMe), 4.68 (1H, br, m, OCH), 6.22 (1H, br s, OH), 6.73 (1H, d, J 8.4 Hz, ArH Ortho to OMe), 6.89 (1H, dd, J 8.4, 2.0 Hz, ArH para to cyclopentyloxy), 7.0 (1H, d, J 2.0 Hz, ArH ortho to cyclopentyloxy, 7.1-7.5 (5H, m, C6 H5), and 8.37 (3H, s, pyrazine H3, H5 H6).
c) (±)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-hydroxyphenylethyl]-3,5-dichloropyridine
From Intermediate 11 (2.0 g, 12.3 mmol) and Intermediate 2 (3.65 g, 12.3 mmol). Purification by column chromatography (SiO2 ; 0-2% MeOH/CH2 Cl2) afforded the title compound (1.74 g) as a white solid. m.p. 129°-130° C. δH (CDCl3) 1.5-1.9 (8H, br, m, (CH2)4), 2.65 (1H, br s, OH), 3.85 (3H, s, OMe), 3.92 (1H, d, J 14 Hz, CHA HB pyridine), 3.98 (1H, d, J 14 Hz, CHA HB pyridine), 4.57 (1H, br, m, OCH), 6.7-6.9 (3H, m, ArH Ortho+2×ArH meta to OMe), 7.2-7.4 (5H, m, C6 H5), and 8.36 (2H, s, pyridine H2, H6).
d) 4-[2-(4-Bromophenyl)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-hydroxyethyl]pyridine
From 4-picoline (2.0 ml, 1.90 g, 20.4 mmol) and Intermediate 26 (7.30 g, 19.5 mmol). Purification by column chromatography (SiO2 ; gradient elution 50-75%, EtOAc/hexane) gave the title compound (7.77 g) as a pale yellow foamy solid. Found: C, 63.82; H, 5.58; N, 2.96. C25 H26 BrNO3 requires C, 64.11; H, 5.60; N, 2.99%. δH (CDCl3) 1.5-1.9 (8H, br, m, (CH2)4), 2.7 (1H, br s, OH), 3.46 (1H, d, J 13.1 Hz, CHA HB pyridine), 3.54 (1H, d, J 13.1 Hz, CHA HB pyridine), 3.82 (3H, s, OMe), 4.64 (1H, br m, OCH), 6.75-6.9 (5H, m, C6 H3 +pyridine H3, H5), 7.21 (2H, ca. d, J 8.7 Hz, ArH of C6 H4), and 8.29 (2H, ca. d, J 6.0 Hz, pyridine H2, H6); νmax. (CDCl3) 3604, 1605, 1513, and 1256 cm-1 ; m/z (ESI) 470 (M+ +2, 20%), 468 (M+, 18), 377 (52), 375 (55), 95 (13), and 94 (100).
e) (±)-4-{2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-[4-(4,4-dimethyl-2-oxazolinyl)phenyl]-2-hydroxyethyl}pyridine
From 4-methylpyridine (1.45 g, 1.52 ml, 15.6 mmol) and Intermediate 14 (5.82 g, 14.9 mmol). Trituration with Et2 O gave the title compound (6.61 g) as an off-white solid. δH (CDCl3) 1.37 (6H, s, CMe), 1.55-1.8 (8H, m, (CH2)4), 2.7 (1H, v. br s, OH) 3.56 (2H, br s, CH2 pyridine), 3.82 (3H, s, OMe), 4.10 (2H, s, oxazoline CH2), 4.63 (1H, m, OCH), 6.75-6.9 (5H, m, ArH), 7.37 (2H, d, J 8.6 Hz, pyridine H3, H5), 7.85 (2H, d, J 7.3 Hz, ArH ortho to oxazoline) and 8.29 (2H, br s, pyridine H2, H6); νmax. (CDCl3) 3603, 1649, 1512, and 1257 cm-1 ; m/z (ESI) 487 (M+ +1, 100%), and 394 (61).
f) 4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-hydroxy-2-(2-thienyl)ethyl]pyridine
From 4-picoline (0.94 g, 10.1 mmol)in THF (80 ml) and Intermediate 18 (3.06 g, 10.1 mmol)in THF (20 ml). Chromatography (SiO2 ; Et2 O to EtOAc/hexane, 4:1) afforded the title compound (3.32 g) as a white foam m.p. 57°-67° C. (Found C, 69.82; H, 6.42; N, 3.41. C23 H25 NO3 S requires C, 69.85; H, 6.37; N, 3.54%); δH (CDCl3) 1.5-2.0 (8H, m, (CH2)4), 3.0 (1H, br s, OH), 3.50 (1H, d, J 13.2 Hz pyridine CHA HB), 3.58 (1H, d, J 13.2 Hz, pyridine CHA HB), 3.83 (3H, s, OMe), 4.64 (1H, m, OCH), 6.75-6.8 (1H, m, ArH of C6 H3), 6.85-7.05 (6H, m, 2×ArH of C6 H3 +pyridine H3, H5 +thiophene H3, H4), 7.25 (1H, dd, J 4.7, 1.7 Hz, thiophene H5), and 8.29 (2H, ca d, J 6.0 Hz, pyridine H2, H6); m/z (ESI) 418 (M+ +Na, 10%), 396 (M+ +1, 100), 303 (35), 95 (12), and 94 (72).
The alcohol was then dehydrated using the procedure described in Example 7.
INTERMEDIATE 8
(±)-4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-1-hydroxy-2-(4-pyridyl) ethyl]pyridine
n-BuLi (1.45M in hexanes; 5.1 ml, 7.41 mmol) was added dropwise at -70° C. to a solution of 4-methylpyridine (0.69 g, 7.41 mmol) in THF (20 ml). After 0.5 h a solution of Intermediate 5 (2.0 g, 6.73 mmol) in THF (10 ml) was added dropwise over 5 min. The reaction mixture was stirred for 0.5 h at -70° C. then at RT for 0.5 h. Water (50 ml) was added and the mixture extracted with EtOAc (3×60 ml). The extract was washed with brine (80 ml), dried (MgSO4), and concentrated in vacuo. The residue was subjected to chromatography (SiO2 ; EtOAc to EtOAc/CH3 OH, 9:1) to afford the title compound (2.33 g) as a white amorphous solid m.p. 99°-103° C; δH (CDCl3) 1.5-2.0 (9H, br, m, (CH2)4 +OH), 3.49 (2H, d, J 2.3 Hz, CH2 COH), 4.65 (1H, br m, OCHCH2), 6.7-6.9 (5H, m, ArH ortho to OMe+2×ArH meta to OMe+pyridine H3, H5), 7.20 (2H, dd, J 4.6, 1.6 Hz, pyridine H3, H5), 8.22 (2H, dd, J 4.6, 1.6 Hz, pyridine H2, H6), and 8.40 (2H, dd, J 4.6, 1.6 Hz, pyridine H2, H6); m/z 390 (M+ 3%), 298 (21), 297 (14), 230 (21), 229 (91), 151 (100), 106 (22), 93 (27), 78 (12), and 41 (23).
INTERMEDIATE 9
1-(3-Cyclopentyloxy-4-methoxyphenyl)-1-phenylethene
To a cold suspension (0° C.) of methyl triphenylphosphonium bromide (53.6 g; 0.15 mol) in THF (500 ml) under a nitrogen atmosphere was added n-BuLi (1.6M in hexanes; 94 ml, 0.15 mol) dropwise and the reaction mixture stirred at 0° C, for 1 h. A solution of Intermediate 2 (29.6 g, 0.1 mol) in THF (100 ml) was added dropwise and the stirred reaction mixture allowed to warm to RT over 3 h. The mixture was poured into 10% NH4 Cl solution (600 ml) and extracted with CH2 Cl2 (2×500 ml). The combined organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residual slurry was triturated with hot hexane (500 ml), the precipitated phosphine oxide filtered off and the filtrate evaporated in vacuo to yield the title compound (28.85 g) as a yellow oil. δH (CDCl3) 1.5-2.0 (8H, br m, (CH2)4), 3.85 (3H, s, OMe), 4.71 (1H, br m, OCH), 5.38 (2H, dd, J 10.5, 1.3 Hz, C═CH2), 6.75-6.9 (3H, m, C6 H3), and 7.3-7.5 (5H, m, C6 H5).
INTERMEDIATE 10
a) (±)-3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-hydroxy-2-phenylethyl]-2-methoxypyrazine
n-BuLi (1.6M in hexanes; 6 ml, 12 mmol) was added dropwise at 4° C. to a solution of N,N-diisopropylamine (1.85 ml, 13 mmol) in THF (40 ml). After 0.5 h, 2-methoxy-3-methylpyrazine (1.28 ml, 11 mmol) was added dropwise at -70° C. and the mixture stirred for 2 h at this temperature. A solution of Intermediate 2 (3.26 g, 11 mmol) in THF (20 ml) was added over 10 min at -70° C. and the mixture stirred for a further 1 h and then allowed to warm to RT. The reaction mixture was partitioned between CH2 Cl2 (75 ml) and saturated NaHCO3 (100 ml). The organic layer was separated, combined with further CH2 Cl2 extracts (2×75 ml), dried (MgSO4) and concentrated in vacuo. The residue was subjected to chromatography (SiO2 ; CH2 Cl2) to afford the title compound (2.94 g) as a white foam. δH (CDCl3) 1.5-2.0 (8H, br m, (CH2)4), 3.63 (1H, d, J 14 Hz, CHH pyrazine), 3.77 (1H, d, J 14 Hz, CHH pyrazine), 3.79 (3H, s, OMe ortho to cyclopentyloxy), 3.97 (3H, s, pyrazine OMe), 4.67 (1H, br m, OCH), 6.72 (1H, dd, J 8.4 Hz, ArH ortho to OMe), 6.77 (1H, s, OH), 6.91 (1H, dd, J 8.4 Hz, 2.0 Hz, ArH para to cyclopentyloxy), 7.00 (1H, d, J 2.0 Hz, ArH ortho to cyclopentyloxy), 7.1-7.5 (5H, m, C6 H5), and 7.85-7.95 (2H, m, pyrazine H5, H6).
b) (±)-2-[-2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-hydroxy-2-phenylethyl]-4-methylpyridine
From 2,4-dimethylpyridine (1.7 ml, 14.5 mmol) and Intermediate 2 (4.30 g, 14.5 mmol). Purification by chromatography (SiO2 ; CH2 Cl2) afforded the title compound (1.23 g) as a colourless oil (Found: C, 77.07; H, 7.10; N, 3.25. C26 H29 NO3 requires C, 77.39; H, 7.24; N, 3.47%); δH (CDCl3) 1.4-1.9 (8H, br m, (CH2)4), 2.25 (3H, s, pyridine Me), 3.60 (2H, s, CH2 pyridine), 3.77 (3H, s, OMe), 4.68 (1H, br m, OCH), 6.72 (1H, d, J 8.5 Hz, ArH ortho to OMe), 6.8-6.95 (3H, m, ArH para to cyclopentyloxy+pyridine H3, H5), 7.02 (1H, d, J 2.2 Hz, ArH ortho to cyclopentyloxy), 7.1-7.3 (3H, m, meta and para ArH of C6 H5), 7.46 (2H, ca d, J 8.5 Hz, ortho ArH of C6 H5), and 8.23 (1H, ca d, J 6 Hz, pyridine H6); m/z (ESI) 404 (M+ +1, 72%), 387 (13), and 386 (100).
c) (±)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-hydroxy-2-phenylethyl]pyrimidine
From 4-methylpyrimidine (1.0 ml) and Intermediate 2 (3.98 g). Purification by chromatography (SiO2 ;CH2 Cl2) afforded the title compound (2.56 g) as a white solid; δH (CDCl3) 1.5-2.0 (8H, br m, (CH2)4), 3.66 (2H, s, CH2 pyrimidine), 3.77 (3H, s, OMe), 4.65 (1H, br m, OCH), 6.58 (1H, s, OH), 6.72 (1H, d, J 8.4 Hz, ArH ortho to OMe), 6.85 (1H, dd, J 8.4, 2.2 Hz, ArH para to cyclopentyloxy), 6.98 (1H, d, J 2.2 Hz, ArH ortho to cyclopentyloxy), 7.07 (1H, d, J 5.2 Hz, pyrimidine H5), 7.15-7.45 (5H, m, C6 H5), 8.53 (1H, d, J 5.2 Hz, pyrimidine H6), and 8.99 (1H, s, pyrimidine H2).
d) (±)-3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-hydroxy-2-phenylethyl]pyridazine
From 3-methylpyridazine (1.0 ml) and Intermediate 2 (3.98 g). Purification by chromatography (SiO2 ; EtOH--CH2 Cl2) afforded the title compound (4.02 g) as an off-white solid.
INTERMEDIATE 11
3,5-Dichloro-4-methylpyridine
3,5-Dichldropyridine (2.04 g, 13.5 mmol) in THF (5 ml) was added dropwise to a solution of LDA [prepared from diisopropylamine (1.9 ml, 13.5 mmol) and n-BuLi (1.6M; 8.4 ml, 13.5 mmol)] in THF (25 ml) at -70° C. After stirring at this temperature for 5 min, iodomethane (0.85 ml, 13.5 mmol) was added and the reaction mixture stirred for a further 1.5 h at -70° C. Saturated NaHCO3 (20 ml) and CH2 Cl2 (20 ml) were added, the organic phase separated, dried (MgSO4), and concentrated in vacuo. The residue was subjected to chromatography (SiO2 ; Et2 O/hexane, 1:3) to afford the title compound (1.16 g) as a pale yellow solid. δH (CDCl3) 2.46 (3H, s, Me), and 8.36 (2H, s, pyridine H2, H6).
INTERMEDIATE 12
(4-Bromophenyl)(3-cyclopentyloxy-4-methoxyphenyl)ketone
A solution of Intermediate 4 (8.00 g, 29.5 mmol) in THF (50 ml) at -70° C. was treated with n-BuLi (19.4 ml, 31.0 mmol, 1.6M solution in hexanes). The slightly yellow solution was stirred at -70° C. for 0.5 h then a solution of 4-bromobenzaldehyde (5.46 g, 29.5 mmol) in THF (50 ml) was added via cannula. The reaction was allowed to warm to RT over 2 h then quenched with water (25 ml) and extracted with Et2 O (2×50 ml). The extract was dried (MgSO4) and concentrated in vacuo to give a pale yellow oil which was dissolved in CH2 Cl2 (150 ml) and treated with manganese dioxide (19.24 g, 0.22 mol). The mixture was stirred vigorously for 20 h at RT then filtered through Celite® and the residue washed with CH2 Cl2 (5×50 ml). The filtrate was concentrated in vacuo to give an off-white solid which was triturated with hexane to give the title compound (7.50 g) as a white solid; δH (CDCl3) 1.55-2.05 (8H, m, (CH2)4), 3.92 (3H, s, OMe), 4.83 (1H, m, OCH), 6.89 (1H, d, J 8.4 Hz, ArH ortho to OMe), 7.33 (1H, dd, J 8.4, 2.0 Hz, ArH para to OMe), 7.42 (1H, d, J 2.0 Hz, ArH ortho to cyclopentyloxy), and 7.55-7.7 (4H, m, C6 H4); νmax. (CDCl3) 2248, 1652, 1590, and 1270 cm-1 ; m/z (ESI) 399 (M+ +2+Na, 100%), 397 (M+ +Na, 90), 296 (16), and 236
INTERMEDIATE 13
Ethyl (E)-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl) propenoate
A mixture of Intermediate 1 (26.62 g, 0.12 mol), ethyl-4-pyridylacetate (19.92 g, 0.12 mol, 1 eq) and ammonium acetate (18.63 g, 0.24 g, 2 eq) in glacial acetic acid (200 ml) was stirred at 120° C. under nitrogen for 20 h. The solution was cooled to RT and the acid removed in vacuo. The orangy/brown residue was taken up in saturated NaHCO3 solution to pH 8.5 and the aqueous layer extracted several times with EtOAc. The combined organic layer was washed (brine), dried (MgSO4) and evaporated to dryness to give a yellow solid. Recrystallisation from toluene/hexane (1st crop) then toluene (2nd crop) followed by column chromatography (hexane-EtOAc/hexane, 7:3) gave the title compound as a white crystalline solid. m.p. 109°-110° C. δH (CDCl3) 1.27 (3H, t, J 7.1 Hz, CH2 CH3), 1.45-1.8 (8H, br m, cyclopentyl H's), 3.81 (3H, s, OMe), 4.16 (1H, br m, OCH), 4.25 (2H, q, J 7.1 Hz, CH2 CH3), 6.43 (1H, d J 2.0 Hz, ArH ortho to cyclopentyloxy), 6.73 (1H, d, J 8.4 Hz, ArH ortho to OMe), 6.80 (1H, dd, J 2.0, 8.4 Hz, ArH para to cyclopentyloxy), 7.22 (2H, dd, J 1.6, 4.5 Hz, pyridine H3, H5), 7.83 (1H, s, HC═C) and 8.64 (2H, dd, J 1.6, 4.5 Hz, pyridine H2, H6).
INTERMEDIATE 14
4-(4,4-dimethyl-2-oxazolinyl)-3'-cyclopentyloxy-4'-methoxyphenyl) ketone
A solution of 2-(4-bromophenyl)-4,4-dimethyloxazoline (A. J. Meyers, D. L. Temple, D. Haidukewych and E. D. Milhelich J. Org. Chem, 39, 2787, 1974) (53.25 g, 0.21 mol) in THF (200 ml) was added dropwise to magnesium turnings (6.0 g, 0.25 g atoms). The reaction was stirred for 2 h at RT, then a solution of Intermediate 1 (46.0 g, 0.21 mol) in THF (200 ml) was added dropwise. The reaction was stirred for 16 h then heated to reflux for 1 h, cooled to RT and quenched with ammonium chloride solution (200 ml). The layers were separated and the aqueous layer extracted with EtOAc (2×250 ml). The organic layer was washed with brine (250 ml), dried (MgSO4), then concentrated in vacuo to give an orange oil. The crude oil was dissolved in CH2 Cl2 (350 ml) and treated with manganese dioxide (137 g, 1.58 mol) then stirred vigorously for 72 h. The mixture was filtered through Celite® and the residue washed with CH2 Cl2 (300 ml). The filtrate was concentrated in vacuo and the residue triturated with Et2 O to give the title compound (59.4 g) as an off white amorphous powder m.p. 159° C. δH (CDCl3) 1.41 (6H, s, CMe2), 1.5-2.1 (8H, m, (CH2)4), 3.92 (3H, s, OMe), 4.15 (2H, s, oxazoline CH2), 4.84 (1H, m, OCH), 6.89 (1H, d, J 8.4 Hz, ArH ortho to OMe), 7.35 (1H, dd, J 2.0, 8.4 Hz, ArH para to OMe), 7.43 (1H, d, J 2 Hz, ArH ortho to cyclopentyloxy), 7.78 (2H, d, J 8.5 Hz, ArH), and 8.03 (2H, d, J 8.5 Hz, ArH); νmax (CDCl3) 1648 and 1271 cm-1 ; m/z (ESI) 394 (M+ +1, 100 %).
The following Intermediate was prepared in a manner similar to the compound of Example 7a.
INTERMEDIATE 15
(E) and (Z) isomers of 4-{2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-[4-(4,4-dimethyl-2-oxazolinyl)phenyl]ethenyl}pyridine
From the alcohol of Intermediate 7e (4.57 g, 9.8 mmol), trifluoroacetic anhydride (2.47 g, 1.66 ml, 11.8 mmol) and triethylamine (0.99 g, 1.36 ml, 11.8 mmol). A portion (100 mg) of the residue was subjected to chromatography (SiO2 ; EtOAc) to give the title compound (68 mg) as a yellow foam. δH (CDCl3) 1.39, 1.41 (6H, s, CMe2), 1.5-1.95 (8H, m, (CH2)4), 3.85, 3.88 (3H, s, OMe), 4.11, 4.14 (2H, s, oxazoline CH2), 4.55, 4.69 (1H, m, OCH), 6.6-6.7 (1H, m, ArH), 6.8-6.85 (3H, m, ArH), 6.91 (1H, d, J 6.2 Hz, pyridine H3, H5), 7.23, 7.38 (2H, d, J 8.2 Hz, ArH), 7.9-8.0 (2H, m, ArH) and 8.3-8.45 (2H, m, pyridine H2, H6); νmax (CDCl3) 1735, 1646, 1597 and 1318 cm-1 ; m/z (ESI) 469 (M+, 100%).
INTERMEDIATE 16
(±)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(2-furyl)-2-hydroxyethyl]pyridine
n-Butyllithium (1.6M solution in hexane; 16.9 ml, 27 mmol) was added to a stirred solution of furan (1.84 g, 1.96 ml, 27 mmol) in THF (25 ml) at -70° C. After 1 h at -70° C., a solution of Intermediate 1 (4.0 g, 18 mmol) in THF (10 ml) was added over 10 min. The reaction mixture was stirred at -70° C. for 0.75 h, warmed to RT over 0.75 h, then quenched with water (100 ml) and extracted with Et2 O (3×60 ml). The extract was washed with brine (100 ml), dried (MgSO4), and concentrated in vacuo. The residual orange-yellow oil was subjected to chromatography (SiO2 ; CH2 Cl2 /hexane, 3:1, then Et2 O/hexane, 1:1) to give (3-cyclopentyloxy-4-methoxyphenyl)(2-furyl)methanol (3.2 g, 61%) as a colourless unstable oil; νmax. (neat) 3500 cm-1.
The alcohol (3.2 g) was stirred with manganese (IV) oxide (10 g) in CH2 Cl2 (100 ml) at RT for 3 h. The mixture was filtered through Celite® and the filtrate concentrated in vacuo. The residual dark oil was subjected to chromatography (SiO2) to give (3-cyclopentyloxy-4-methoxyphenyl)-(2-furyl)ketone (1.9 g); νmax (neat) 1620 cm-1.
n-Butyllithium (1.6M solution in hexanes; 4.2 ml, 6.64 mmol) was added to a solution of a 4-methylpyridine (0.62 g, 0.65 ml, 6.64 mmol) in THF (25 ml) at -70° C. After 0.5 h, a solution of the crude ketone (1.9 g, ca. 6.6 mmol) in THF (5 ml) was added, stirred for 1 h at -70° C., then at RT for 0.25 h. The reaction mixture was quenched with water (50 ml) and extracted with EtOAc (3×50 ml). The extract was dried (MgSO4), concentrated in vacuo, and the residual red oil subjected to chromatography (SiO2 ; EtOAc/hexane, 3:2) to afford the title compound (1.23 g, 49%) as a pale yellow oil; δH (CDCl3) 1.5-1.9 (8H, br m, (CH2)4), 2.84 (1H, br s, OH), 3.30 (1H, d, J 13.2 Hz, CHA HB pyridine), 3,59 (1H, d, J, 13.2 Hz, CHA HB pyridine), 3.82 (3H, s, OMe), 4.65 (1H, br m OCH), 6.24 (1H, dd, J 3.3, 0.7 Hz, furan H3), 6.35 (1H, dd, J 3.3, 1.8 Hz, furan H4), 6.75-6.85 (3H, m, C6 H3), 6.85 (2H, dd, J 4.5, 1.6 Hz, pyridine H3, H5), 7.43 (1H, dd, J 1.8, 0.7 Hz, furan H5), and 8.33 (2H, dd, J 4.5, 1.6 Hz, pyridine H2, H6); m/z (ESI) 402 (M+ +23, 20%), 380 (M+ +1, 35), 287 (100), 95 (28), and 94 (97).
INTERMEDIATE 17
(3-Cyclopentyloxy-4-methoxyphenyl)-2-thienylmethanol
Thienyllithium (1.0M solution in THF; 14 ml, 14.0 mmol) was added to a solution of Intermediate 1 (3.04 g, 13.8 mmol) in THF (30 ml) at -70° C. After 0.25 h, the reaction mixture was allowed to warm to RT, stirred for 0.75 h, then quenched with 10% aqueous NH4 Cl solution (25 ml) and extracted with Et2 O (3×40 ml). The extract was dried (MgSO4), concentrated in vacuo, and the orange residue subjected to chromatography (SiO2 ; Et2 O/hexane, 1:1) to afford the title compound (3.88 g), as an off-white solid m.p. 79°-80° C. (from hexane-diisopropyl ether) (Found: C, 67.10; H, 6.65. C17 H20 O3 S requires C, 67.08; H, 6.62%); δH (CDCl3) 1.5-2.0 (8H, br m, (CH2)4), 2.37 (1H, br s, OH), 3.84 (3H, s, OM), 4.75 (1H, br m OCH), 5.99 (1H, br s, CHOH), 6.8-7.1 (5H, m, C6 H3+thiophene H3, H4), and 7.2-7.3 (1H, m, thiophene H5) m/z (ESI) 327 (M+ +Na, 100%).
INTERMEDIATE 18
(3-Cyclopentyloxy-4-methoxyphenyl)-2-thienylketone
A solution of Intermediate 17 (3.37 g, 11.08 mmol) in CH2 Cl2 (200 ml) was stirred vigorously with manganese (IV) oxide (15 g) for 2 h. The mixture was filtered through Celite® and the filtrate concentrated in vacuo to afford the title compound (3.32 g), as an amber oil (Found: C, 67.38; H, 6.08. C17 H18 O3 S requires C, 67.53; H, 6.00%); δH (CDCl3) 1.55-2.0 (8H, br m, (CH2)4), 3.93 (3H, s, OMe), 4.85 (1H, br m, OCH), 6.92 (1H, d, J 8.3 Hz, ArH ortho to OMe), 7.16 (1H, dd, 4.9, 3.8 Hz, thienyl H4), 7.46 (1H, d, J 2.0 Hz, ArH ortho to cyclopentyloxy), 7.53 (1H, dd, J 8.3, 2.0 Hz ArH para to OMe), and 7.65-7.7 (2H, m, thienyl H3, H5); m/z (ESI) 627 (2M+ +Na, 90%), 325 (M+ +Na, 100), and 303 (M+, 10).
EXAMPLE 1
a) (E) and (Z) isomers of 4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]pyridine
Intermediate 7a (3.13 g, 8.05 mmol) was dissolved in toluene (70 ml) containing 4-toluenesulphonic acid monohydrate (1.91 g, 10.05 mmol) and the mixture heated to reflux for 1 h. The reaction mixture was poured into aqueous NaOH (10%; 100 ml) and stirred for 5 min. The mixture was extracted with Et2 O (3×70 ml) and the organic extract washed with water (80 ml), and brine (80 ml), then dried (MgSO4), and concentrated in vacuo to afford a mixture of the title compounds (3.0 g) as a viscous pale yellow oil. δH (CDCl3) 1.5-2.1 (8H, br m, (CH2)4), 3.82 (major) and 3.84 (minor) (3H, s, OMe), 4.8 (1H, br m, OCHCH2), 6.6-7.4 (11H, m, ArH ortho to OMe+2×ArH meta to OMe+C6 H5 +pyridine H3, H5), and 8.2-8.35 (2H, m, pyridine H2, H6); m/z 372 (M+ +1, 12%), 371 (M+, 40), 304 (21), 303 (100), 302 (72) and 274 (22).
The following compounds were prepared using a similar procedure:
b) (E) and (Z) isomers of 2-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]pyrazine
From Intermediate 7b (570 mg, 1.5 mmol) and 4-toluene sulphonic acid (about 20 mg). Upon completion, the reaction mixture was concentrated in vacuo then subjected to chromatography (SiO2 ; Et2 O) to afford the title compound (520 mg) as a colourless oil. δH (CDCl3) 1.5-2.0 (8H, br m, (CH2)4), 3.84 and 3.86 (3H, s, OMe), 4.58 and 4.72 (1H, br m, OCH), 6.65-7.5 (9H, m, C6 H5 +C=CH+ArH ortho to OMe+2×ArH meta to OMe), 7.90 and 8.04 (1H, d, J 1.5 Hz, pyrazine H3), 8.18 and 8.21 (1H, d, J 2.5 Hz, pyrazine H6), and 8.45 and 8.48 (1H, m, pyrazine H5).
c) (E) and (Z) isomers of 3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]-2-methoxypyrazine
From Intermediate 10a (2.94 g, 7.0 mmol) and 4-toluene-sulphonic acid (about 20 mg) as described for Intermediate 7b to afford the title compound (2.67 g) as a yellow oil. δH (CDCl3) 1.5-2.0 (8H, br m, (CH2)4), 3.80, 3.81, 3.83, 3.86 (2×3H, s, 2×OMe), 4.50, 4.70 (1H, br m, OCH), 6.60-7.5 (9H, m, C6 H5 +C=CH+ArH ortho to OMe+2×ArH meta to OMe) and 7.7-7.95 (2H, m, pyrazine H5, H6).
d) (i) (E) 4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]-3,5-dichloropyridine
(ii) (Z) 4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]-3,5-dichloropyridine
From Intermediate 7c (1.60 g, 3.58 mmol) and 4-toluene-sulphonic acid (0.85 g). Purification by column chromatography (SiO2 ; CH2 Cl2) afforded: i) (E) title compound (960 mg) as an off-white solid m.p. 138.5°-140° C. δH (CDCl3) 1.5-2.0 (8H, br m, (CH2)4), 3.88 (3H, s, OMe), 4.72 (1H, br m, OCH), 6.59 (1H, s, C═CH), 6.85 (1H, d, J 8.4 Hz, ArH ortho to OMe), 6.90 (1H, d, J 2.0 Hz, ArH ortho to cyclopentyloxy), 6.95 (1H, dd, J 8.4, 2.0 Hz, ArH para to cyclopentyloxy), 7.0-7.1 (2H, m, H2, H6 of C6 H5), 7.15-7.3 (3H, m, H3, H4, H5 of C6 H5), and 8.35 (2H, s, pyridine H2, H6). and ii) (Z) title compound (240 mg) as an off-white solid. m.p. 155°-156.5° C. δH (CDCl3) 1.4-1.8 (8H, br m (CH2)4), 3.80 (3H, s, OMe), 4.42 (1H, br m OCH), 6.52 (1H, d, J 2.00 Hz, m ArH ortho to cyclopentyloxy), 6.56 (1H, s, C═CH), 6.57 (1H, dd, J 8.4, 2.0 Hz, ArH para to cyclopentyloxy), 6.68 (1H, d, J 8.4 Hz, ArH ortho to OMe), 7.3-7.45 (5H,m, C6 H5), and 8.37 (2H, s, pyridine H2, H6).
e) (E) and (Z) isomers of 2-[2-(3-Cyclopentyloxy-4-methoxy phenyl)-2-phenylethenyl]-4-methylpyridine
From Intermediate 10b (1.15 g, 2.85 mmol). Purification by chromatography (SiO2 ; EtOAc) afforded the title compound (1.2 g) as a pale yellow solid; δH (CDCl3) 1.4-1.9 (8H, br m, (CH2)4), 2.04 (major), 2.09 (minor) (3H, s, pyridine Me), 3.85 (major), 3.88 (minor) (3H, s, OMe), 4.58 (minor), 4.72 (major) (1H, br m, OCH), 6.4-7.5 (11H, m, C6 H5 +C6 H3 +pyridine H3, H5 +C═CH), 8.5-8.55 (1H, m, pyridine H6). 1 Hn.m.r indicates a 2:1 E/Z ratio.
f) (E) and (Z) isomers of 4-[2-(3-Cyclopentyloxy-4-methoxy phenyl)-2-phenylethenyl]pyrimidine
From Intermediate 10c (2.55 g). Purification by chromatography (SiO2 ; Et2 O) afforded the title compound (1.20 g) as a pale yellow foam; δH (CDCl3) 1.5-2.0 (8H, br m, (CH2)4), 3.88, 3.90 (3H, s, OMe), 4.60, 4.70 (1H, br m, OCH), 6.44, 6.64 (1H, d, J 5.2 Hz, pyrimidine H5), 6.65-7.0 (3H, m, C6 H3), 7.2-7.45 (6H, m, C6 H5 +C═CH), 8.26, 8.32 (1H, d, J 5.2 Hz, pyrimidine H6), and 9.10, 9.12 (1H, ca s, pyrimidine H2).
g) (E) and (Z) isomers of 3-[2-(3-Cyclopentyloxy-4-methoxy phenyl)-2-phenylethenyl]pyridazine
From Intermediate 10d (4.0 g). Purification by chromatography (SiO2 ; Et2 O) afforded the title compound (2.07 g) as a pale yellow solid (Found: C, 77.59; H, 6.49; N, 7.24. C24 H24 N2 O2 requires C, 77.39; H, 6.50; N, 7.52%); δH (CDCl3) 1.5-1.9 (8H, br m, (CH2)4), 3.88, 3.90 (3H, s, OMe), 4.58, 4.70 (1H, br m, OCH), 6.6-7.5 (11H, m, C6 H5 +C6 H3 +C═CH+pyridazine H4, H5+), and 8.85-8.90 (1H, m, pyridazine H6) (1 Hnmr indicates a 3:2 E/Z ratio); m/z (ESI) 396 (M+ +1+Na, 57%), 395 (M+ +Na, 100), 374 (66), 373 (78), and 305 (16).
EXAMPLE 2
(E) and (Z) isomers of 4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethenyl]pyridine
A mixture of Intermediate 6 (0.48 g, 1.58 mmol), Cs2 CO3 (0.56 g, 1.73 mmol), and cyclopentyl bromide (0.26 g, 1.743 mmol) in DMF (20 ml) was stirred at RT overnight. A further portion of Cs2 CO3 (0.20 g, 0.61 mmol) and cyclopentyl bromide (0.28 g, 1.86 mmol) was added, the mixture stirred for 1.5h then concentrated in vacuo. The residue was subjected to chromatography (SiO2 ; EtOAc/CH3 OH/Et3 N, 100:1:0.4) to afford the title compound (0.42 g) as a white solid. m.p. 136°-138° C. (cyclohexane); δH (CDCl3) 1.5-2.0 (8H, br m (CH2)4), 3.84 (3H, s, OMe), 4.65 (1H, br m OCHCH2), 6.7-6.9 (6H, m, ArH ortho to OMe+2×ArH meta to OMe+C═CH+pyridine H3, H5), 7.08 (2H, dd, J 4.5, 1.5 Hz, pyridine pyridine H3 ', H5 '), 8.32 (2H, dm, J 5.0 Hz pyridine H2, H6), and 8.55 (2H, dd, J 4.5, 1.5 Hz, pyridine H2 ', H6 '); m/z 372 (M+ 28%), 305 (37), 304 (100), 303 (95), 275 (18), and 41 (18).
EXAMPLE 3
a) (E) and (Z) isomers of 4-[2-(3-Cyclopentyloxy-4-methoxy phenyl)-2-phenylethenyl] phenol
A mixture of Intermediate 9 (2.94 g, 10 mmol), 4-bromophenol (2.16 g, 12.5 mmol), Et3 N (2.52 g, 25 mmol), tri-o-tolyl phosphine (0.06 g, 0.2 mmol) and palladium acetate (0.022 g, 0.1 mmol) was heated in a bomb at 140° C. for 16 h. Upon cooling, the reaction mixture was diluted with NH4 Cl (10%; 50 ml) and CH2 Cl2 (50 ml). The organic layer was separated and the aqueous layer extracted with CH2 Cl2 (50 ml). The combined organic layer was dried (MgSO4), filtered and concentrated. Purification by column chromatography (SiO2 ; hexane/Et2 O, 1:1) yielded the title compound (1:1 mixture of isomers) (0.8 g) as a yellow foam. δH (CDCl3) 1.2-1.9 (8H, br m, (CH2)4), 3.81, 3.83 (3H, s, OMe), 4.59, 4.69 (1H, br m, OCH), 5.5, 5.63 (1H, br s, OH), 6.55-7.0 (8H, m, C6 H3 +C6 H4 +C═CH), and 7.15-7.35 (5H, m, C6 H5) [N.B. 1 Hn.m.r. indicates ca 1:1 E/Z mixture of isomers); m/z (ESI) 410 (M+ +1+Na, 18%), 409 (M+ +Na, 100) 387 (M+ +1, 62), 319 (38), 318 (22), 301 (19), 236 (22), and 135 (20).
The following compounds were prepared using a similar procedure:
b) (E) and (Z) isomers of 3-[2-(3-Cyclopentyloxy-4-methoxy phenyl)-2-phenylethenyl] benzoic acid
From Intermediate 9 (2.94 g, 10 mmol) and 3-bromobenzoic acid (5.03 g, 25 mmol). Purification by column chromatography [SiO2 ; 10%, CH3 OH/CH2 Cl2 ] furnished the title compounds (2 g) as a viscous yellow oil. δH (CDCl3) 1.45-2.0 (8H, br m, (CH2)4), 3.86, 3.87 (3H, s, OMe), 4.55, 4.7 (1H, br m, OCH), 6.65-8.25 (13H, m, C6 H5 +C6 H4 +C6 H3 +C═CH), (CO2 H not observed) [N.B. 1 Hn.m.r. indicates ca 1:1 E/Z mixture of isomers]; m/z (ESI) 437 (M+ +23, 60%), 301 (67), 281 (100), and 259 (52).
c) (E) and (Z) isomers of 4-[2-(3-Cyclopentyloxy-4-methoxy phenyl)-2-phenylethenyl] anisole
From Intermediate 9 (1.19 g, 4.04 mmol) and 4-bromoanisole (0.757 g, 4.05 mmol). Purification by column chromatography [SiO2 ; hexane/Et2 O, 4:1] furnished the title compounds (0.78 g) as a yellow oil. δH (CDCl3) 1.5-2.0 (8H, br m, (CH2)4), 3.72, 3.73 (3H, s, OMe), 3.82, 3.86 (3H, s, OMe), 4.58, 4.67 (1H, br m, OCH), 6.6-6.9 (6H, m, C6 H3 +2×ArH ortho to OMe+C═CH), 6.93, 7.00 (2H, d, J 8.5 Hz, 2×ArH meta to OMe) and 7.15-7.35 (5H, m, C6 H5) [N.B. 1 Hn.m.r. indicates ca 1:1 E/Z mixture of isomers]; m/z (ESI) 424 (M+ +1+Na, 20%), 423 (M+ +Na, 100%), 374 (12), 281 (20), 198 (12), 132 (12) and 86 (12).
d) (E) and (Z) isomers of Methyl 4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]benzoate
From Intermediate 9 (2.94 g, 10 mmol) and methyl 4-bromobenzoate (2.69 g, 12.5 mmol) to afford the title compounds (3.35 g) as a yellow gum; δH (CDCl3) 1.4-2.0 (8H, br m, (CH2)4), 3.86, 3.87 (6H, s, OMe+CO2 Me), 4.54, 4.67 (1H, br m, OCH), 6.6-7.4 (11H, m, C6 H5 +C6 H3 +C═CH+2×ArH meta to CO2 Me), and 7.75-7.85 (2H, m, 2×ArH ortho to CO2 Me) [N.B. 1 Hn.m.r. indicates ca 1:1 E/Z mixture of isomers]; m/z (ESI) 429 (M+ +1+Na, 28%), 362 (18), 361 (28), 330 (70), and 329 (68).
e) (E) and (Z) isomers of 3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]pyridine
From Intermediate 9 (1.00 g, 3.4 mmol) and 3-bromopyridine (1.28 g, 8.1 mmol). Purification by chromatography (SiO2 ; Et2 O) afforded the title compound (0.50 g) as a pale yellow gum; δH (CDCl3) 1.45-2.0 (8H, br m, (CH2)4), 3.85 (major), 3.87 (minor) (3H, s, OMe), 4.55 (minor), 4.69 (major) (1H, br m, OCH), 6.65-7.5 (11H, m, C6 H5 +C6 H3 +pyridine H4, H5 +C═C), and 8.2-8.45 (2H, m, pyridine H2, H6).
EXAMPLE 4
(E) and (Z) isomers of 4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]acetoxybenzene
To a stirred solution of the compound of Example 3a (0.2 g, 0.52 mmol) in CH2 Cl2 (5 ml), under a nitrogen atmosphere, was added Et3 N (0.101 g, 0.14 ml, 1 mmol) followed by acetyl chloride (0.0785 g, 0.071 ml, 1 mmol). The reaction mixture was stirred at RT for 4 h then poured into saturated NaHCO3 (10 ml). The organic layer was separated and the aqueous layer extracted with CH2 Cl2. The combined organic layer was dried (MgSO4), filtered, and the solvent removed in vacuo to furnish the title compounds (0.222 g) as a colourless oil. δH (CDCl3) 1.5-1.9 (8H, br m, (CH2)4), 2.23, 2.24 (3H, s, OCOMe), 3.83, 3.86 (3H, s, OMe), 4.56, 4.67 (1H, br m, OCH), and 6.7-7.4 (13H, m, C6 H5 +C6 H4 +C6 H3 +C═CH)[N.B. 1 Hn.m.r. indicates ca 1:1 E/Z mixture of isomers]; m/z (ESI) (M+ +Na, 100%), 319 (20), 281 (29), 191 (48), 127 (50 ) and 55 (54).
EXAMPLE 5
(E) and (Z) isomers of Methyl 3-[2-(3-cyclopentyloxy-4-methoxy phenyl)-2-phenylethenyl]benzoate
To a cold (0° C.) solution of the compound of Example 3b (0.25 g, 0.6 mmol) in CH3 OH (20 ml) was added SOCl2 (0.357 g, 0.22 ml, 3 mmol) dropwise and the reaction mixture was stirred at RT for 3 h. The solvent was evaporated in vacuo, the residue dissolved in CH2 Cl2 (20 ml) and washed with saturated NaHCO3 (20 ml). The organic phase was separated and the aqueous phase extracted with CH2 Cl2 (20 ml). The combined organic layer was dried (MgSO4), filtered and the solvent evaporated in vacuo to yield the title compound (0.215 g) as a yellow oil. δH (CDCl3) 1.4-2.0 (8H, br m, (CH2)4), 3.82, 3.83, 3.84, 3.85 (6H, s, OMe+CO2 M), 4.54, 4.69 (1H, br m, OCH), and 6.65-7.85 (13H, m, C6 H4 +C6 H4 +C6 H3 +C═CH) [N.B. 1 Hn.m.r. indicates ca 1:1 E/Z mixture of isomers]; m/z (ESI) 429 (M+ +1, 25%), 361 (22), 329 (100), 159 (12), 102 (15), and 60 (75).
EXAMPLE 6
(E) and (Z) isomers of 4-[2-(4-Aminophenyl)-2-(3-cyclopentyioxy-4-methoxyphenyl)ethenyl]pyridine
Water (15 ml) and trifluoroacetic acid (10 ml) were added to Intermediate 13 (6.1 g) in CH2 Cl2 (15 ml) at 0° C. and the mixture allowed to warm to RT. After 6 h, the reaction mixture was concentrated in vacuo and the residue partitioned between 10% hydrochloric acid (50 ml) and EtOAc (50 ml). The aqueous layer was separated, basified to pH 14 with 20% sodium hydroxide solution, and extracted with CH2 Cl2 (3×50 ml). The extract was dried (MgSO4) and concentrated in vacuo to give the crude title compound (4.2 g). A portion (0.40 g) was subjected to chromatography (SiO2); EtOAc) to afford the title compound (0.29 g); δH (CDCl3) 1.45-2.0 (8H, br m, (CH2)4), 3.80 (2H, br s, NH2), 3.87, 3.90 (3H, s, OMe), 4.58, 4.70 (1H, br m, OCH), 6.6-7.2 (10H, C6 H4 +C6 H3 +pyridine H3, H5 +C═CH), and 8.3-8.4 (2H, m, pyridine H2, H6); m/z (ESI) 388 (M+ +1, 100%).
EXAMPLE 7
a) (E) and (Z) isomers of 4-[2-(4-Bromophenyl)-2-(3-cyclopentyloxy-4-methoxyphenyl)ethenyl]pyridine
A solution of Intermediate 7d (7.52 g, 16.0 mmol) and triethylamine (4.05 g, 5.60 ml, 40.0 mmol) in CH2 Cl2 (100 ml) was cooled to 0° C. and trifluoroacetic anhydride (3.70 g, 2.50 ml, 17.6 mmol) was added dropwise. The orange-red solution was allowed to warm to RT over 20 h then water (25 ml) was added. The mixture was extracted with CH2 Cl2 and the extract was dried (MgSO4), concentrated in vacuo and subjected to chromatography to give the title compound (4.73 g) as a white amorphous powder. (Found: C, 66.66; H, 5.27; N, 2.99. C25 H24 BrNO2 requires C, 66.67; H, 5.37; N, 3.11%); δH (CDCl3) 1.45-1.95 (8H, br, m, (CH2)4), 3.86, 3.88 (3H, s, OMe), 4.55, 4.70 (1H, br m, OCH), 6.6-6.95 (6H, m, C6 H3, +pyridine H3, H5)+C═CH), 7.06, 7.21 (2H, d, J 8.4 Hz, ArH of C6 H4), 7.4-7.5 (2H, m, ArH of C6 H4), and 8.36 (2H, ca. d, J 6.0 Hz, pyridine H2, H6) (1 H n.m.r. indicates a 1:1 E/Z mixture); νmax (CDCl3) 1597, 1514, and 1251 cm-1 ; m/z (ESI) 452 (M+ +2+Na, 100%), 450 (M+ +Na, 88), 384 (30) and 382 (28).
The following compound was prepared to a manner similar to compound of example 7a.
b) (Z)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(2-furyl) ethenyl]pyridine
From the compound of Intermediate 15 (1.0 g, 2.64 mmol) in CH2 Cl2 (30 ml), triethylamine (0.4 g, 0.55 ml, 3.96 mmol) and trifluoroacetic anhydride (0.61 g, 0.41 ml, 2.91 mmol). Work up [includes treatment with 10% NaOH solution (25 ml)] and chromatography (SiO2 ; EtOAc/hexane, 7:3) afforded the title compound (0.78 g) as a pale pink solid m.p. 122°-123° C.; (Found: C, 76.37; H, 6.46; N, 3.85. C23 H43 NO3 requires C, 76.43; H, 6.41; N, 3.88%); δH (CDCl3) 1.45-1.9 (8H, br m, (CH2)4), 3.90 (3H, s, OMe), 4.65 (1H, br m, OCH), 6.07 (1H, d, J 3.3 Hz, furan H3), 6.41 (1H, dd, J 3.3, 1.8 Hz, furan H4), 6.75-6.9 (5H, m, C6 H3 +pyridine H3, H5), 7.03 (1H, s, C═CH), 7.49 (1H, d, J 1.6 Hz, furan H5), and 8.33 (2H, ca. d, J 4.6 Hz, pyridine H2, H6); m/z (ESI) 362 (M+ +1, 100%), 294 (45).
EXAMPLE 8
(E) and (Z) isomers of -4-[-1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethenyl]benzoic acid hydrochloride
Intermediate 15 (4.25 gm 8.8 mmol) in 10% aqueous HCl (15 ml) was heated to reflux for 20 min. Aqueous NaOH solution (5M; 20 ml) and EtOH (15 ml) were then added and heating continued for a further 2 h. The reaction was cooled to RT and acidified to pH 1 with 10% aqueous HCl. The mixture was extracted with CHCl3 (10×100 ml), the organic extract was dried (MgSO4) and concentrated in vacuo to give the title compound (2.83 g) as a yellow solid; δH (d4 -MeOH) 1.45, 1.8 (8H, br m, (CH2)4), 3.86, 3.88 (3H, s, OMe), 4.66, 4.74 (1H, br m, OCH), 6.65-7.65 (8H, m, C═CH+C6 H3 +pyridine H3, H5, +ArH meta to CO2 H), 8.05, 8.13 (2H, d, J ca 0.8 Hz, ArH ortho to CO2 H), and 8.46, 8.55 (2H, d, J ca. 6 Hz, pyridine H2, H6) (N.B. CO2 H and HCl not observed) (2H, d, J 8.2 Hz, ArH); νmax (Nujol) 1710, and 1633 cm-1 ; m/z (ESI) 416 (M+ +1, 100%).
EXAMPLE 9
(E) and (Z) isomers of t-Butyl N-{4-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethenyl]phenyl}carbamate
A mixture of diphenyl phosphoryl azide (0.61 g, 0.48 ml, 2.2 mmol), Intermediate 14 (1.00 g, 2.2 mmol), triethylamine (0.49, 0.68 ml, 4.9 mmol) and t-butanol (25 ml) was heated to reflux for 20 h. The mixture was concentrated in vacuo and the resulting brown oil partitioned between CH2 Cl2 (30 ml) and 5% citric acid solution (30 ml). The organic layer was separated, washed with water (20 ml), NaHCO3 solution (20 ml), and brine (20 ml), then dried (MgSO4) and concentrated in vacuo to give a red oil; which was subjected to chromatography to give the title compound. (0.60 g, 56%) as a yellow foamy solid. δH (CDCl3) 1.52, 1.54 (9H, s, CMe3), 1.65-1.9 (8H, br m, (CH2)4), 3.86, 3.89 (3H, s, OMe), 4.56, 4.70 (1H, m, OCH), 6.6-7.4 (11H, m, ArH+C═CH+NCO), and 8.34 (2H, d, J 5.2 Hz, pyridine H2, H6). (1 H n.m.r. indicates ca. 1:1 mixture of isomers); νmax (CHCl3) 3441, 1730, 1596, 1518 and 1157 cm-1 ; m/z (ESI) 487 (M+ +1, 75%), 472 (12), and 431 (100).
The activity and selectivity of compounds according to the invention was demonstrated in the following tests.
1. Isolated Enzyme
The potency and selectivity of the compounds of the invention was determined using a battery of distinct PDE isoenzymes as follows:
PDE I, rabbit heart
PDE II, rabbit heart
PDE III, rabbit heart
PDE IV, HL60 cells
PDE V, HL60 cells
The enzymes were purified to kinetic homogeneity using standard chromatographic techniques.
Phosphodiesterase activity was assayed as follows. The reaction was conducted in 150 μl of standard mixture containing (final concentrations): 50 mM TES-NaOH buffer (pH 7.5), 10 mM MgCl2, 0.1 μM [3 H]-cAMP and vehicle or various concentrations of the test compounds. The reaction was initiated by addition of enzyme and conducted at 30° C. for between 5 to 30 min. The reaction was terminated by addition of 50 μl 2% trifluoroacetic acid containing [14 C]-5'AMP for determining recovery of the product. An aliquot of the sample was then applied to a column of neutral alumina and the [3 H]-cAMP eluted with 10 ml 0.1 TES-NaOH buffer (pH 8). The [3 H]-5'AMP product was eluted with 2 ml 2M NaOH into a scintillation vial containing 10 ml of scintillation cocktail. Recovery of [3 H]-5'AMP was determined using the [14 C]-5'AMP and all assays were conducted in the linear range of the reaction.
A gene encoding human PDE IV has been cloned from human monocytes (Livi, et al., 1990, Molecular and Cellular Biology, 10, 2678). Using similar procedures we have cloned human PDE IV genes from a number of sources including eosinophils, neutrophils, lymphocytes, monocytes, brain and neuronal tissues. These genes have been transfected into yeast using an inducible vector and various recombinant proteins have been expressed which have the biochemical characteristics of PDE IV (Beavo and Reifsnyder, 1990, TIPS, 11, 150). These recombinant enzymes, particularly the human eosinophil recombinant PDE IV, have been used as the basis of a screen for potent, selective PDE IV inhibitors.
Compounds, according to the invention, cause a concentration-dependent inhibition of recombinant PDE IV at 0.1-1000 nM with little or no activity against PDE I, II, III or V at concentrations up to 100 μM.
2. The Elevation of cAMP in Leukocytes
The effect of compounds of the invention on intracellular cAMP was investigated using human neutrophils or guinea pig eosinophils. Human neutrophils were separated from peripheral blood, incubated with dihydrocytochalasin B and the test compound for 10 min and then stimulated with FMLP. Guinea pig eosinophils were harvested by peritoneal lavage of animals previously treated with intraperitoneal injections of human serum. Eosinophils were separated from the peritoneal exudate and incubated with isoprenaline and test compound. With both cell types, suspensions were centrifuged at the end of the incubation, the cell pellets were resuspended in buffer and boiled for 10 min prior to measurement of cAMP by specific radioimmunoassay (DuPont).
The most potent compounds induced a concentration-dependent elevation of cAMP in neutrophils and/or eosinophils at concentrations of 0.1 nM to 1 μM.
3. Suppression of Leukocyte Function
Compounds of the invention were investigated for their effects on superoxide generation and chemotaxis of human neutrophils. Neutrophils were separated from peripheral blood, incubated with dihydrocytochalasin B for superoxide generation only and test compound prior to stimulation with FMLP. The most potent compounds caused a concentration-dependent inhibition of superoxide generation and chemotaxis at concentrations of 0.1 nM to 1 μM.
Lipopolysaccharide (LPS)-induced synthesis of tumour necrosis factor (TNF) by human peripheral blood monocytes (PBM) is inhibited by compounds of the invention at concentrations of 0.01 nM to 10 μM.
4. Relaxation of Constricted Airway Smooth Muscle in vitro
The effects of compounds of the invention on guinea-pig isolated tracheal smooth muscle were investigated. Isolated tracheal rings were suspended in organ baths and immersed in oxygenated Krebs' solution. The smooth muscle was contracted with sub-maximal concentrations of histamine or carbachol prior to the addition of increasing concentrations of test compound to the organ baths. The most potent compounds caused a concentration-dependent reversal of both histamine and carbachol-induced contractions at concentrations of 1 nM to 100 μM. The compounds were generally more potent in reversing histamine-induced tone than carbachol-induced tone.
5. Effects on Cardiac Muscle in vitro
Compounds of the invention have been tested for their effects on isolated cardiac muscle. Right atrial and papillary muscles were dissected out from the hearts of guinea pigs and suspended in organ baths for measuring the rate (chronotropic) of spontaneously beating atria and force (inotropic) of the electrically stimulated papillary muscle. In these preparations, selective PDE IV inhibitors such as rolipram do not have any direct effects whereas selective PDE III inhibitors such as milrinone have positive chronotropic and inotropic effects. The non-specific PDE inhibitor theophylline, which is used in asthma as a bronchodilator, also causes significant cardiovascular changes such as tachycardia. Selective PDE IV inhibitors have advantage over theophylline, therefore, through reduced cardiovascular side effects. The most potent and selective compounds of the invention had no direct effects on the atrial and papillary muscles in vitro at concentrations up to 10 μM but in combination with PDE III inhibitors, these inhibitors showed an enhancement of chronotropic and inotropic activity, typical of selective type IV inhibitors.
6. Anti-inflammatory Activity in vivo
Interleukin-5 (IL-5)-induced pleural eosinophilia in the rat (Lisle, et al, 1993, Br. J. Pharmacol. 108, 230p) is inhibited by compounds of the invention given orally at doses of 0.0001 to 10.0 mg/kg. The most potent compounds cause a dose-dependent reduction in migrating eosinophils with ED50 s of 0.003 to 0.03 mg/kg p.o.
Compounds of the invention also reduce the inflammatory responses induced in rats by platelet activating factor (PAR).
7. Anti-allergic Activity in vivo
Compounds of the invention have been tested for effects on an IgE-mediated allergic pulmonary inflammation induced by inhalation of antigen by sensitised guinea pigs. Guinea pigs were initially sensitised to ovalbumin under mild cyclophosphamide-induced immunosuppression, by intraperitoneal injection of antigen in combinations with aluminium hydroxide and pertussis vaccine. Booster doses of antigen were given two and four weeks later and at six weeks, animals were challenged with aerosolised ovalbumin whilst under cover of an intraperitoneally administered anti-histamine agent (mepyramine). After a further 48 h, bronchial alveolar lavages (BAL) were performed and the numbers of eosinophils and other leukocytes in the BAL fluids were counted. The lungs were also removed for histological examination for inflammatory damage. Administration of compounds of the invention (0.001-10 mg/kg i.p. or p.o.), up to three times during the 48 h following antigen challenge, lead to a significant reduction in the eosinophilia and the accumulation of other inflammatory leukocytes. There was also less inflammatory damage in the lungs of animals treated with compounds of the invention.
8. Effects on Pulmonary Dynamics
Compounds of the invention have been tested for their effects on ozone-induced hyperreactivity of the airways of guinea pigs. Following the inhalation of ozone, guinea pigs become very much mere sensitive to the bronchoconstrictor effects of inhaled histamine than naive animals (Yeadan et al, 1992, Pulmonary Pharm., 5, 39). There is a pronounced shift to the left (10-30 fold) of the dose response curve to histamine and a highly significant increase in the maximum increase in pulmonary resistance. Compounds of the invention administered 1 h prior to ozone by the intraperitoneal or oral (0.001-10 mg/kg) route caused a dose-dependent inhibition of ozone-induced hyperreactivity.
Compounds of the invention are free from adverse effects following repeated overdosage to rats or dogs. For example, oral administration of 125 mg/kg/day of active compounds to rats for 30 days is not associated with adverse toxicity.

Claims (14)

We claim:
1. A compound of formula (1) ##STR19## wherein Y represents a halogen atom or a group --OR1, where R1 is an C1-6 alkyl group optionally substituted by one or more halogen atoms;
X is --O--, --S-- or --N(R6)--, where R6 is a hydrogen atom or an C1-6 alkyl group;
R2 is a C3-8 cycloalkyl or C3-8 cycloalkenyl group optionally substituted by one, two or three substituents selected from the group consisting of halogen, C1-6 alkyl, hydroxyl, and C1-6 alkoxy;
R3 and R4, which may be the same or different, is each a group --(CH2)n Ar, where n is zero or an integer 1, 2 or 3, and Ar is a monocyclic or bicyclic C6-12 aryl group, or a monocyclic or bicyclic heteroaryl group which is a member selected from the group consisting of pyrrolyl, furyl, thienyl, imidazolyl, N-methylimidazolyl, N-ethylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolyl, isoindolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolinyl and 5,6,7,8-tetrahydroisoquinolinyl;
and wherein the aryl and heteroaryl groups defining R3 and R4 are optionally substituted by one, two, three or more substituents selected from the group consisting of an atom or group R8 or --Alk1 (R8)m wherein R8 is a halogen atom, or an amino (--NH2), substituted amino, nitro, cyano, hydroxyl (--OH), substituted hydroxyl, cycloalkoxy, formyl [HC(O)--], carboxyl (--CO2 H), esterified carboxyl, thiol (--SH), substituted thiol, --C(O)Alk1, --SO3 H, --SO2 Alk1, --SO2 NH2, --SO2 NHAlk1, --SO2 N[Alk1 ]2, --CONH2, --CONHAlk1, C--ON[Alk1 ]2, --NHSO2 H, --NHSO2 Alk1, --N[SO2 Alk1 ]2, --NHSO2 NH2, --NHSO2 NHAlk1, --NHSO2 N[Alk1 ]2, --NHC(O)Alk1, or --NHC(O)OAlk1 group; Alk1 is a straight or branched C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene chain optionally interrupted by one, two, or three --O--, or --S-- atoms or --S(O)p--, where p is an integer 1 or 2, or --N(R6)-- as defined above; and m is zero or an integer 1, 2 or 3; and
R5 is a hydrogen atom or an C1-6 alkyl group optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxyl, and C1-6 alkoxy;
or a salt, solvate, hydrate or N-oxide thereof.
2. A compound according to claim 1 wherein X is --O--.
3. A compound according to claim 1 or claim 2, wherein Y is a group --OR1 where R1 is a methyl group.
4. A compound according to claim 1 wherein R2 is a cyclopentyl group.
5. A compound according to claim 1 wherein Y is a --OCH3 group, X is --O--, R2 is a cyclopentyl group and wherein R3 and R4 is each independently a group --Ar.
6. A compound according to claim 5 wherein R3 is a group Ar where Ar is an unsubstituted or substituted monocyclic aryl or monocyclic nitrogen-containing heteroaryl group and R4 is a group Ar where Ar is an unsubstituted or substituted monocyclic nitrogen-containing heteroaryl group.
7. A compound according claim 6 wherein the monocyclic aryl group is an unsubstituted or substituted phenyl group, the monocyclic heteroaryl group is an unsubstituted or substituted furyl or thienyl group and the monocyclic nitrogen-containing heteroaryl group is an unsubstituted or substituted pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl group.
8. A compound according to claim 7 wherein the nitrogen-containing heteroaryl group is a substituted or unsubstituted pyridyl group.
9. A compound according to claim 1 selected from the (E) and (Z) isomers of:
4-[2-(3-Cyclopentyioxy-4-methoxyphenyl)-2-(2-furyl) ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(2-thienyl)ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]-3-methylimidazole;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]pyridine;
4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethenyl]pyridine;
(4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-fluorophenylethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-trifluoromethylphenyl)ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(2-methoxyphenylethenyl)]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-methoxyphenyl)ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-methylphenyl) ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(3-methylphenyl)ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(3-cyclopentyloxy-4-methoxyphenyl)ethenyl]pyridine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]-3,5-dichloropyridine;
2-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]pyridine;
4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethenyl]aniline;
4-[1-(3-Cyclopenxyloxy-4-methoxyphenyl0-2-(4-pyridyl)ethenyl]benzoic acid;
Ethyl N-{4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl) ethenyl]phenyl}carbamate;
N-{4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2(4-pyridyl)ethenyl]phenyl}N'-ethylurea;
N-{4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)]-2-(4-pyridyl)ethenyl}phenylacetamide;
3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]pyridine;
4-[2-2(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethenyl]pyrimidine;
4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-hydroxymethylphenyl)ethenyl]pyridine;
4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethenyl]benzamide;
Ethyl-4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-phenylethenyl]benzoate;
N-{4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethenyl]phenyl}methanesulphonamide; or
each enantiomer thereof; and the salts, solvates, hydrate and N-oxides thereof.
10. A pharmaceutical composition comprising a compound of formula (1) ##STR20## wherein Y represents a halogen atom or a group --OR1, where R1 is an C1-6 alkyl group optionally substituted by one or more halogen atoms;
X is --O--, --S-- or --N(R6)--, where R6 is a hydrogen atom or an C1-6 alkyl group;
R2 is a C3-8 cycloalkyl or C3-8 cycloalkenyl group optionally substituted by one, two or three substituents selected from the group consisting of halogen, C1-6 alkyl, hydroxyl, and C1-6 alkoxy;
R3 and R4, which may be the same or different, is each a group --(CH2)n Ar, where n is zero or an integer 1, 2 or 3, and Ar is a monocyclic or bicyclic C6-12 aryl group, or a monocyclic or bicyclic heteroaryl group which is a member selected from the group consisting of pyrrolyl, furyl, thienyl, imidazolyl, N-methylimidazolyl, N-ethylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolyl, isoindolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolinyl and 5,6,7,8-tetrahydroisoquinolinyl;
and wherein the aryl and heteroaryl groups defining R3 and R4 are optionally substituted by one, two, three or more substituents selected from the group consisting of an atom or group R8 or --Alk1 (R8)m wherein R8 is a halogen atom, or an amino (--NH2), substituted amino, nitro, cyano, hydroxyl (--OH), substituted hydroxyl, cycloalkoxy, formyl [HC(O)--], carboxyl (--CO2 H), esterified carboxyl, thiol (--SH), substituted thiol, --C(O)Alk1, --SO3 H, --SO2 Alk1, --SO2 NH2, --SO2 NHAlk1, --SO2 N[Alk1 ]2, --CONH2, --CONHAlk1, C-ON[Alk1 ]2, --NHSO2 H, --NHSO2 Alk1, --N[SO2 Alk1 ]2, --NHSO2 NH2, --NHSO2 NHAlk1, --NHSO2 N[Alk1 ]2, --NHC(O)Alk1, or --NHC(O)OAlk1 group; Alk1 is a straight or branched C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene chain optionally interrupted by one, two, or three --O--, or --S-- atoms or --S(O)p--, where p is an integer 1 or 2, or --N(R6)-- as defined above; and m is zero or an integer 1, 2 or 3; and
R5 is a hydrogen atom or an C1-6 alkyl group optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxyl, and C1-6 alkoxy;
or a salt, solvate, hydrate or N-oxide thereof;
together with one or more pharmaceutically acceptable carriers, excipients or diluents.
11. A method of preventing or treating an inflammatory disease by means of the therapeutic effect achieved by elevating the intra-cellular levels of adenosine 3',5'-cyclic monophosphate (cAMP) within inflammatory leukocytes of a patient suffering from such an inflammatory disease, comprising the step of administering to said patient an amount of a selective inhibitor of one or more of the phosphodiesterase (PDE) IV family of isoenzymes, which is sufficient to obtain said therapeutic effect, said inhibitor being one or more compounds of the formula: ##STR21## wherein Y represents a halogen atom or a group --OR1, where R1 is an C1-6 alkyl group optionally substituted by one or more halogen atoms;
X is --O--, --S-- or --N(R6)--, where R6 is a hydrogen atom or an C1-6 alkyl group;
R2 is a C3-8 cycloalkyl or C3-8 cycloalkenyl group optionally substituted by one, two or three substituents selected from the group consisting of halogen, C1-6 alkyl, hydroxyl, and C1-6 alkoxy;
R3 and R4, which may be the same or different, is each a group --(CH2)n Ar, where n is zero or an integer 1, 2 or 3, and Ar is a monocyclic or bicyclic C6-12 aryl group, or a monocyclic or bicyclic heteroaryl group which is a member selected from the group consisting of pyrrolyl, furyl, thienyl, imidazolyl, N-methylimidazolyl, N-ethylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolyl, isoindolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolinyl and 5,6,7,8-tetrahydroisoquinolinyl;
and wherein the aryl and heteroaryl groups defining R3 and R4 are optionally substituted by one, two, three or more substituents selected from the group consisting of an atom or group R8 or --Alk1 (R8)m, wherein R8 is a halogen atom, or an amino (--NH2), substituted amino, nitro, cyano, hydroxyl (--OH), substituted hydroxyl, cycloalkoxy, formyl [HC(O)--], carboxyl (--CO2 H), esterified carboxyl, thiol (--SH), substituted thiol, --C(O)Alk1, --SO3 H, --SO2 Alk1, --SO2 NH2, --SO2 NHAlk1, --SO2 N[Alk1 ]2, --CONH2, --CONHAlk1, C--ON[Alk1 ]2, --NHSO2 H, --NHSO2 Alk1, --N[SO2 Alk1 ]2, --NHSO2 NH2, --NHSO2 NHAlk1, --NHSO2 N[Alk1 ]2, --NHC(O)Alk1, or --NHC(O)OAlk1 group; Alk1 is a straight or branched C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene chain optionally interrupted by one, two, or three --O--, or --S-- atoms or --S(O)p--, where p is an integer 1 or 2, or --N(R6)-- as defined above; and m is zero or an integer 1, 2 or 3; and
R5 is a hydrogen atom or an C1-6 alkyl group optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxyl, and C1-6 alkoxy;
or a salt, solvate, hydrate or N-oxide thereof.
12. A method according to claim 11 wherein the inflammatory disease is asthma and the therapeutic effect which is achieved is both an anti-inflammatory effect and a bronchodilator effect.
13. A method according to claim 11 wherein the inflammatory disease is one or more members selected from the group essentially consisting of inflammatory airway disease, chronic bronchitis, eosinophilic granuloma, inflammatory arthritis, atopic dermatitis, urticaria, allergic rhinitis, adult respiratory distress syndrome, and allergic conjunctivitis.
14. A method according to claim 11 wherein the therapeutically effective amount of the selective inhibitor is in the range of from about 100 ng to 100 mg per kg of body weight of the patient being treated.
US08/462,118 1992-12-23 1995-06-05 Styryl derivatives as anti-inflammatory agents Expired - Lifetime US5580888A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/462,118 US5580888A (en) 1992-12-23 1995-06-05 Styryl derivatives as anti-inflammatory agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929226830A GB9226830D0 (en) 1992-12-23 1992-12-23 Chemical compounds
GB9226830 1992-12-23
US17204793A 1993-12-22 1993-12-22
US08/462,118 US5580888A (en) 1992-12-23 1995-06-05 Styryl derivatives as anti-inflammatory agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US17204793A Continuation 1992-12-23 1993-12-22

Publications (1)

Publication Number Publication Date
US5580888A true US5580888A (en) 1996-12-03

Family

ID=10727118

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/462,118 Expired - Lifetime US5580888A (en) 1992-12-23 1995-06-05 Styryl derivatives as anti-inflammatory agents

Country Status (10)

Country Link
US (1) US5580888A (en)
EP (1) EP0626957B1 (en)
JP (1) JP3581714B2 (en)
AT (1) ATE177097T1 (en)
AU (1) AU678797B2 (en)
CA (1) CA2129040C (en)
DE (1) DE69323732T2 (en)
ES (1) ES2131668T3 (en)
GB (1) GB9226830D0 (en)
WO (1) WO1994014800A1 (en)

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693659A (en) * 1994-06-23 1997-12-02 Celltech Therapeutics Limited Substituted oxime derivatives and processes for their preparation
US5710170A (en) * 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
US5710160A (en) * 1996-02-22 1998-01-20 Merck Frosst Canada, Inc. Diphenyl pyridyl ethane derivatives as PDE IV inhibitors
US5739144A (en) * 1993-03-10 1998-04-14 Celltech Therapeutics Limited Trisubstituted phenyl derivatives
US5776958A (en) * 1993-12-22 1998-07-07 Celltech Therapeutics, Limited Trisubstituted phenyl derivatives and processes for their preparation
US5780478A (en) * 1994-06-22 1998-07-14 Celltech Therapeutics, Limited Tetra-substituted phenyl derivatives
US5780477A (en) * 1994-06-22 1998-07-14 Celltech Therapeutics, Limited Trisubstituted phenyl derivatives and processes for their preparation
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US5798373A (en) * 1995-12-21 1998-08-25 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives useful as PDE IV inhibitors
US5849770A (en) * 1995-12-21 1998-12-15 Celltech Therapeutics Ltd. Tri-substituted phenyl derivatives useful as PDE IV inhibitors
US5859034A (en) * 1996-12-04 1999-01-12 Celltech Therapeutics, Limited Tri-substituted phenyl compounds which have useful pharmaceutical activity
US5866593A (en) * 1993-12-22 1999-02-02 Celltech Therapeutics Ltd. Trisubstituted phenyl derivatives and processes for their preparation
US5891896A (en) * 1995-12-21 1999-04-06 Celltech Therapeutics Ltd. Tri-substituted phenyl derivatives useful as PDE IV inhibitors
US5922741A (en) * 1996-04-24 1999-07-13 Celltech Therapeutics Ltd. 5-aminopyrazoles useful as tyrosine kinase inhibitors
US5958935A (en) * 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
US5962492A (en) * 1993-03-10 1999-10-05 Celltech Therapeutics Limited 2 cyclo(alkyl and alkenyl) phenyl-alkenylyl heteroaryl compounds and pharmaceutical compositions containing same
US6048866A (en) * 1997-03-14 2000-04-11 Celltech Therapeutics, Limited Substituted 2-anilinopryimidines useful as protein kinase inhibitors
US6057329A (en) * 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
US6080790A (en) * 1992-10-23 2000-06-27 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparations
US6093716A (en) * 1996-09-16 2000-07-25 Celltech Therapeutics, Limited Substituted 2-pyrimidineamines and processes for their preparation
US6096747A (en) * 1992-06-15 2000-08-01 Celltech Therapeutics Limited Phenylaminocarbonyl derivatives and processes for their preparation
US6114333A (en) * 1996-10-28 2000-09-05 Celltech Therapeutics Ltd. 2-Pyrimidineamine derivatives and processes for their preparation
US6133257A (en) * 1997-06-20 2000-10-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
WO2001046151A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6399636B2 (en) 2000-03-23 2002-06-04 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6448274B2 (en) 2000-05-25 2002-09-10 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor
US6479554B2 (en) * 1996-08-12 2002-11-12 Celgene Corporation Immunotherapeutic agents
WO2003018579A1 (en) 2001-08-29 2003-03-06 Merck Frosst Canada & Co. Alkyne-aryl phosphodiesterase-4 inhibitors
US6579983B1 (en) 1999-06-18 2003-06-17 Celltech R&D Limited 5-cyano-2-aminopyrimidine derivatives
US6600037B1 (en) 1999-10-20 2003-07-29 Celltech R & D Limited 4,5-disubstituted-2-aminopyrimidines
US6677351B2 (en) 2001-05-24 2004-01-13 Merck Frosst Canada & Co. 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US20040102630A1 (en) * 2001-05-29 2004-05-27 Schering Ag CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents
US6943191B1 (en) 1998-02-27 2005-09-13 The United States Of America As Represented By The Department Of Health And Human Services Disubstituted lavendustin A analogs and pharmaceutical composition comprising the analogs
WO2006116718A2 (en) 2005-04-28 2006-11-02 Proteus Biomedical, Inc. Pharma-informatics system
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP2147679A2 (en) 2001-07-25 2010-01-27 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2010095940A2 (en) 2009-02-20 2010-08-26 To-Bbb Holding B.V. Glutathione-based drug delivery system
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2258359A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2266607A2 (en) 1999-10-01 2010-12-29 Immunogen, Inc. Immunoconjugates for treating cancer
EP2275095A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2012044761A1 (en) 2010-09-29 2012-04-05 University Of North Carolina At Wilmington Ladder-frame polyether conjugates
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP4218718A2 (en) 2009-05-06 2023-08-02 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (en) * 1992-12-23 1995-11-21 Celltech Ltd
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
WO1996020175A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation 1,4,4-(trisubstituted)cyclohex-1-ene derivatives as pde iv- and tnf-inhibitors
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
US6268373B1 (en) 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
US5900417A (en) * 1995-12-21 1999-05-04 Smithkline Beecham Corporation 1,3,3-(Trisubstituted)cyclohexanemonomers and related compounds
US6294541B1 (en) 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
JP4373497B2 (en) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド Substituted azabicyclo compounds and their use as inhibitors of TNF and cyclic AMP phosphodiesterase production
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
US6040447A (en) 1997-12-12 2000-03-21 Euro-Celtique S.A. Purine compounds having PDE IV inhibitory activity and methods of synthesis
US6319928B1 (en) 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
CA2367143A1 (en) 1999-04-02 2000-10-12 Euro-Celtique S.A. Purine derivatives having phosphodiesterase iv inhibition activity
WO2008029829A1 (en) * 2006-09-06 2008-03-13 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine derivative and phosphodiesterase (pde) inhibitor containing the same as active ingredient
CN113264886B (en) * 2021-06-09 2022-05-20 辽宁中医药大学 Extraction and separation method of pyridazine compound in purslane and application thereof

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2501443A1 (en) * 1974-01-15 1975-07-24 Pharmascience Lab PHARMACEUTICAL PRODUCTS CONTAINING AT LEAST ONE DIPHENYL-SUBSTITUTED COMPOUND
US4012495A (en) * 1974-03-20 1977-03-15 Schering Aktiengesellschaft 4-(Polyalkoxyphenyl)-2-pyrrolidones
US4153713A (en) * 1975-09-18 1979-05-08 Schering Aktiengesellschaft 4-(Polyalkoxyphenyl)-2-pyrrolidones (II)
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
GB1588639A (en) * 1976-12-03 1981-04-29 Schering Ag 5-(substituted phenyl)-oxazolidinones and sulphur analogues thereof and also a process for their production
US4303649A (en) * 1978-06-15 1981-12-01 Imperial Chemical Industries Limited 1-Phenyl-2-aminoethanol derivatives
WO1987006576A1 (en) * 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
US4792561A (en) * 1986-05-29 1988-12-20 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
US4921862A (en) * 1986-05-29 1990-05-01 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors
EP0393500A1 (en) * 1989-04-17 1990-10-24 Byk Gulden Lomberg Chemische Fabrik GmbH Arylpyridazines, their preparation, their use and pharmaceuticals containing them
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
WO1991015451A1 (en) * 1990-04-05 1991-10-17 Smithkline Beecham Pharma Gmbh Novel derivatives of phenyl-cycloalkanes and -cycloalkenes
WO1991016892A1 (en) * 1990-04-27 1991-11-14 Rorer International (Holdings), Inc. Styryl compounds which inhibit egf receptor protein tyrosine kinase
WO1992000968A1 (en) * 1990-07-10 1992-01-23 Smithkline Beecham Corporation Oxamides
EP0470805A1 (en) * 1990-08-08 1992-02-12 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
WO1992006085A1 (en) * 1990-09-28 1992-04-16 Smith Kline & French Laboratories Limited Phenylpyridinol derivatives as medicaments
WO1992006963A1 (en) * 1990-10-16 1992-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Arylpyridazinones
WO1992007567A1 (en) * 1990-11-06 1992-05-14 Smithkline Beecham Corporation Imidazolidinone compounds
EP0490823A1 (en) * 1990-12-13 1992-06-17 Sandoz Ltd. Dihydro-isoquinoline derivates
US5128358A (en) * 1988-01-19 1992-07-07 Pfizer Inc. Aryl substituted nitrogen heterocyclic antidepressants
EP0511865A1 (en) * 1991-05-01 1992-11-04 American Home Products Corporation Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents
WO1992019594A1 (en) * 1991-05-02 1992-11-12 Smithkline Beecham Corporation Pyrrolidinones
WO1992019602A1 (en) * 1991-04-26 1992-11-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyridazines
US5175167A (en) * 1990-02-09 1992-12-29 Basf Aktiengesellschaft Hetarylalkenes, their preparation and intermediates for their preparation and their use
EP0537742A2 (en) * 1991-10-15 1993-04-21 Mitsubishi Chemical Corporation Styrene derivatives
WO1993019748A1 (en) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor
US5274002A (en) * 1987-04-14 1993-12-28 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
WO1994002465A1 (en) * 1992-07-28 1994-02-03 Rhone-Poulenc Rorer Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF
US5298511A (en) * 1991-10-03 1994-03-29 Imperial Chemical Industries Plc Alkanoic acid derivatives
WO1994012461A1 (en) * 1992-12-02 1994-06-09 Pfizer Inc. Catechol diethers as selective pdeiv inhibitors
US5326898A (en) * 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity

Patent Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2501443A1 (en) * 1974-01-15 1975-07-24 Pharmascience Lab PHARMACEUTICAL PRODUCTS CONTAINING AT LEAST ONE DIPHENYL-SUBSTITUTED COMPOUND
US4015017A (en) * 1974-01-15 1977-03-29 Laboratoires Pharmascience Certain biphenyl derivatives used to treat disorders caused by increased capillary permeability
US4012495A (en) * 1974-03-20 1977-03-15 Schering Aktiengesellschaft 4-(Polyalkoxyphenyl)-2-pyrrolidones
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
US4153713A (en) * 1975-09-18 1979-05-08 Schering Aktiengesellschaft 4-(Polyalkoxyphenyl)-2-pyrrolidones (II)
GB1588639A (en) * 1976-12-03 1981-04-29 Schering Ag 5-(substituted phenyl)-oxazolidinones and sulphur analogues thereof and also a process for their production
US4303649A (en) * 1978-06-15 1981-12-01 Imperial Chemical Industries Limited 1-Phenyl-2-aminoethanol derivatives
WO1987006576A1 (en) * 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
US4792561A (en) * 1986-05-29 1988-12-20 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
US4921862A (en) * 1986-05-29 1990-05-01 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US5274002A (en) * 1987-04-14 1993-12-28 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US5128358A (en) * 1988-01-19 1992-07-07 Pfizer Inc. Aryl substituted nitrogen heterocyclic antidepressants
EP0393500A1 (en) * 1989-04-17 1990-10-24 Byk Gulden Lomberg Chemische Fabrik GmbH Arylpyridazines, their preparation, their use and pharmaceuticals containing them
US5236918A (en) * 1989-04-17 1993-08-17 Byk Gulden Lomberg Chemische Fabrik Gmbh 6-aryl-3-cyanaminopyridazines, their preparation and use and medicaments containing them
US5175167A (en) * 1990-02-09 1992-12-29 Basf Aktiengesellschaft Hetarylalkenes, their preparation and intermediates for their preparation and their use
WO1991015451A1 (en) * 1990-04-05 1991-10-17 Smithkline Beecham Pharma Gmbh Novel derivatives of phenyl-cycloalkanes and -cycloalkenes
WO1991016892A1 (en) * 1990-04-27 1991-11-14 Rorer International (Holdings), Inc. Styryl compounds which inhibit egf receptor protein tyrosine kinase
WO1992000968A1 (en) * 1990-07-10 1992-01-23 Smithkline Beecham Corporation Oxamides
EP0470805A1 (en) * 1990-08-08 1992-02-12 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
WO1992006085A1 (en) * 1990-09-28 1992-04-16 Smith Kline & French Laboratories Limited Phenylpyridinol derivatives as medicaments
WO1992006963A1 (en) * 1990-10-16 1992-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Arylpyridazinones
WO1992007567A1 (en) * 1990-11-06 1992-05-14 Smithkline Beecham Corporation Imidazolidinone compounds
EP0490823A1 (en) * 1990-12-13 1992-06-17 Sandoz Ltd. Dihydro-isoquinoline derivates
US5177085A (en) * 1990-12-13 1993-01-05 Sandoz Ltd. Dihydro-isoquinoline derivatives, processes for their production, pharmaceutical compositions containing them, and their use in treating asthma
WO1992019602A1 (en) * 1991-04-26 1992-11-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyridazines
EP0511865A1 (en) * 1991-05-01 1992-11-04 American Home Products Corporation Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents
WO1992019594A1 (en) * 1991-05-02 1992-11-12 Smithkline Beecham Corporation Pyrrolidinones
US5298511A (en) * 1991-10-03 1994-03-29 Imperial Chemical Industries Plc Alkanoic acid derivatives
EP0537742A2 (en) * 1991-10-15 1993-04-21 Mitsubishi Chemical Corporation Styrene derivatives
US5326898A (en) * 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
WO1993019748A1 (en) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor
WO1994002465A1 (en) * 1992-07-28 1994-02-03 Rhone-Poulenc Rorer Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF
WO1994012461A1 (en) * 1992-12-02 1994-06-09 Pfizer Inc. Catechol diethers as selective pdeiv inhibitors

Non-Patent Citations (40)

* Cited by examiner, † Cited by third party
Title
Ashton, "Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4-methyoxybenzamides and Analogues" J. Med. Chem. 37: 1696-1703 (1994).
Ashton, Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3 (Cyclopentyloxy) 4 methyoxybenzamides and Analogues J. Med. Chem. 37: 1696 1703 (1994). *
Beavo, et al. " Primary Sequence Of Cyclie Nucleotide Phosphodiesterase Isozymes And The Design Of Selective Inhibitors", TIPS 11:150-155 (1990).
Beavo, et al. Primary Sequence Of Cyclie Nucleotide Phosphodiesterase Isozymes And The Design Of Selective Inhibitors , TIPS 11:150 155 (1990). *
Buu Hoi et al., New Method for the Synthesis of , Diarylacetophenones Aminated in the Aromatic Nucleus. Plynitration of Triarylethylenes Chemical Abstracts 61: 16006h (1964). *
Buu Hoi, N. P. et al., Bromination of Some 1,2,2 Triarylethylenes 1261 1263 (1958). *
Buu-Hoi et al., "New Method for the Synthesis of ω,ω-Diarylacetophenones Aminated in the Aromatic Nucleus. Plynitration of Triarylethylenes" Chemical Abstracts 61: 16006h (1964).
Buu-Hoi, N. P. et al., "Bromination of Some 1,2,2-Triarylethylenes" 1261-1263 (1958).
Chemical Abstracts. Registry Handbook Number Section. Printed Issues Columbus US *compounds with registry numbers 95992 21 5; 95971 60 1; 90053 37 5; 82668 18 6; 80395 25 1; 49610 49 3 (1982). *
Chemical Abstracts. Registry Handbook-Number Section. Printed Issues Columbus US *compounds with registry numbers 95992-21-5; 95971-60-1; 90053-37-5; 82668-18-6; 80395-25-1; 49610-49-3 (1982).
El Wakil et al., Study of the proton magnetic resonance of methoxytamoxifen towards ortho substitiution Chemical Abstracts 116: 255248t (1992). *
El-Wakil et al., "Study of the proton magnetic resonance of methoxytamoxifen towards ortho-substitiution" Chemical Abstracts 116: 255248t (1992).
Hirose et al., "Styrene Derivatives and Electrophotpgraphic Photoreceptor Containing Them" Chemical Abstracts 118: 136183z (1993).
Hirose et al., Styrene Derivatives and Electrophotpgraphic Photoreceptor Containing Them Chemical Abstracts 118: 136183z (1993). *
Livi, et al., "Cloning And Expression Of cDNA For A Human Low-Km3 Rolipram-Sensitive Cyclic AMP Phosphodiesterase", Molecular and Cellular Biology, 10:2678 (1990).
Livi, et al., Cloning And Expression Of cDNA For A Human Low K m3 Rolipram Sensitive Cyclic AMP Phosphodiesterase , Molecular and Cellular Biology , 10:2678 (1990). *
Manhas et al., "heterocyclic Compounds XII. Quinazoline Derivatives as Potential Antifertility Agents (1)" J. Het Chem: 711-715 (1979).
Manhas et al., heterocyclic Compounds XII. Quinazoline Derivatives as Potential Antifertility Agents (1) J. Het Chem: 711 715 (1979). *
Meyers, et al., "Oxazolines. XI. Synthesis Of Functionalized Aromatic And Aliphatic Acids. A Useful Protecting Group For Carboxylic Acids Against Grignard And Hydride Reagents", J. Org. Chem., vol. 39:2787 (1974).
Meyers, et al., Oxazolines. XI. Synthesis Of Functionalized Aromatic And Aliphatic Acids. A Useful Protecting Group For Carboxylic Acids Against Grignard And Hydride Reagents , J. Org. Chem. , vol. 39:2787 (1974). *
Mezheritskaya, "Synthesis and properties of carboxonium het=erocyclic systems. VII. Synthesis and properties of 2-benzyl-substituted 1,3-dioxolanium salts" Chem. Abs. 93: 95160j p. 635 (1980).
Mezheritskaya, Synthesis and properties of carboxonium het erocyclic systems. VII. Synthesis and properties of 2 benzyl substituted 1,3 dioxolanium salts Chem. Abs. 93: 95160j p. 635 (1980). *
Nicholson, et al. "Differential Modulation Of Tissue Function And Therapeutic Potential Of Selective Inhibitors Of Cyclic Nucleotide Phosphodiesterase Isoenzymes", TIPS 12:19-27 (1991).
Nicholson, et al. Differential Modulation Of Tissue Function And Therapeutic Potential Of Selective Inhibitors Of Cyclic Nucleotide Phosphodiesterase Isoenzymes , TIPS 12:19 27 (1991). *
O Conner et al., Voltammetry and Controlled Potential Oxidation of 3,4 dimethoxypropenylbenzene at a rotating platinum electrode in unbuffered acetonitrile and in acetonitrile pyridine solution Chemical Abstracts 60(8) 10203.4 (Apr. 13, 1964). *
O'Conner et al., "Voltammetry and Controlled Potential Oxidation of 3,4-dimethoxypropenylbenzene at a rotating platinum electrode in unbuffered acetonitrile and in acetonitrile-pyridine solution" Chemical Abstracts 60(8) #10203.4 (Apr. 13, 1964).
Ramalingam, Deshmukh and Sattur, "Synthesis and Pharmacology of 2,5-Disubstituted 1,3,4-Zxadiazoles" J. Indian Chem. Soc. vol. 58(3) 269-271 (1981).
Ramalingam, Deshmukh and Sattur, Synthesis and Pharmacology of 2,5 Disubstituted 1,3,4 Zxadiazoles J. Indian Chem. Soc. vol. 58(3) 269 271 (1981). *
Reddy et al., "Inhibition of Breast Cancer Cell Growth in Vitro by a Tyrosine Kinase Inhibitor" Cancer Research 52: 3636-3641 (1992).
Reddy et al., Inhibition of Breast Cancer Cell Growth in Vitro by a Tyrosine Kinase Inhibitor Cancer Research 52: 3636 3641 (1992). *
Schneider et al "Catechol Estrogens of the 1,1,2-triphenyl-but-1-ene Type." J. Med. 29 Chem. 1355-1362 (1986).
Schneider et al Catechol Estrogens of the 1,1,2 triphenyl but 1 ene Type. J. Med. 29 Chem. 1355 1362 (1986). *
Schneider et al., "Catechol Estrogens of the 1,1,2-Triphenylbut-1-ene Type: Relationship Between Structure, Estradiol Receptor Affinity, Estrogenic and Antiestrogenic Properties, and Mammary Tumor Inhibiting Activities" J. Med. Chem. 29: 1355-1362 (1986).
Schneider et al., Catechol Estrogens of the 1,1,2 Triphenylbut 1 ene Type: Relationship Between Structure, Estradiol Receptor Affinity, Estrogenic and Antiestrogenic Properties, and Mammary Tumor Inhibiting Activities J. Med. Chem. 29: 1355 1362 (1986). *
Seitz et al., "Fluorotamoxifen. A Caveat on the Generality of Electrophilic Destannylation" Chemical Abstracts 111: 57136k 57133k (1989).
Seitz et al., Fluorotamoxifen. A Caveat on the Generality of Electrophilic Destannylation Chemical Abstracts 111: 57136k 57133k (1989). *
Yeadon, et al., "Mechanisms Contributing To Ozone-Induced Bronchial Hyperreactivity In Guinea-Pigs", Pulmonary Pharm. 5:39 (1992).
Yeadon, et al., Mechanisms Contributing To Ozone Induced Bronchial Hyperreactivity In Guinea Pigs , Pulmonary Pharm. 5:39 (1992). *
Yoneda et al., "The Antiproliferative Effects of Tyrosine Kinase Inhibitors Tyrphostins on a Human Squamous Cell Carcinoma in Vitro and in Nude Mice" Cancer Research 51: 4430-4435 (1991).
Yoneda et al., The Antiproliferative Effects of Tyrosine Kinase Inhibitors Tyrphostins on a Human Squamous Cell Carcinoma in Vitro and in Nude Mice Cancer Research 51: 4430 4435 (1991). *

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096747A (en) * 1992-06-15 2000-08-01 Celltech Therapeutics Limited Phenylaminocarbonyl derivatives and processes for their preparation
US6080790A (en) * 1992-10-23 2000-06-27 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparations
US5962492A (en) * 1993-03-10 1999-10-05 Celltech Therapeutics Limited 2 cyclo(alkyl and alkenyl) phenyl-alkenylyl heteroaryl compounds and pharmaceutical compositions containing same
US5739144A (en) * 1993-03-10 1998-04-14 Celltech Therapeutics Limited Trisubstituted phenyl derivatives
US5962483A (en) * 1993-03-10 1999-10-05 Celltech Therapeutics, Limited Trisubstituted phenyl derivatives and processes for their preparation
US5776958A (en) * 1993-12-22 1998-07-07 Celltech Therapeutics, Limited Trisubstituted phenyl derivatives and processes for their preparation
US5866593A (en) * 1993-12-22 1999-02-02 Celltech Therapeutics Ltd. Trisubstituted phenyl derivatives and processes for their preparation
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US6077854A (en) * 1994-06-21 2000-06-20 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US5780477A (en) * 1994-06-22 1998-07-14 Celltech Therapeutics, Limited Trisubstituted phenyl derivatives and processes for their preparation
US6197792B1 (en) 1994-06-22 2001-03-06 Celltech Therapeutics Limited Tetra-substituted phenyl derivatives and processes for their preparation
US5780478A (en) * 1994-06-22 1998-07-14 Celltech Therapeutics, Limited Tetra-substituted phenyl derivatives
US6297264B1 (en) 1994-06-22 2001-10-02 Celltech Therapeutics Limited Trisubstituted phenyl derivatives and process for their preparation
US5693659A (en) * 1994-06-23 1997-12-02 Celltech Therapeutics Limited Substituted oxime derivatives and processes for their preparation
US5958935A (en) * 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
US6235746B1 (en) 1995-11-20 2001-05-22 Celltech Therapeutics, Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
US5710170A (en) * 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
US5849770A (en) * 1995-12-21 1998-12-15 Celltech Therapeutics Ltd. Tri-substituted phenyl derivatives useful as PDE IV inhibitors
US5891896A (en) * 1995-12-21 1999-04-06 Celltech Therapeutics Ltd. Tri-substituted phenyl derivatives useful as PDE IV inhibitors
US5798373A (en) * 1995-12-21 1998-08-25 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives useful as PDE IV inhibitors
US5710160A (en) * 1996-02-22 1998-01-20 Merck Frosst Canada, Inc. Diphenyl pyridyl ethane derivatives as PDE IV inhibitors
US5922741A (en) * 1996-04-24 1999-07-13 Celltech Therapeutics Ltd. 5-aminopyrazoles useful as tyrosine kinase inhibitors
US6479554B2 (en) * 1996-08-12 2002-11-12 Celgene Corporation Immunotherapeutic agents
US20040019106A1 (en) * 1996-08-12 2004-01-29 Muller George W. Novel immunotherapeutic agents
US7019030B2 (en) 1996-08-12 2006-03-28 Celgene Corporation Immunotherapeutic agents
US20030045726A1 (en) * 1996-08-12 2003-03-06 Muller George W. Novel immunotherapeutic agents
US6093716A (en) * 1996-09-16 2000-07-25 Celltech Therapeutics, Limited Substituted 2-pyrimidineamines and processes for their preparation
US6114333A (en) * 1996-10-28 2000-09-05 Celltech Therapeutics Ltd. 2-Pyrimidineamine derivatives and processes for their preparation
US6552029B1 (en) 1996-10-28 2003-04-22 Celltech R&D Limited 2-pyrimidineamine derivatives and processes for their preparation
US5859034A (en) * 1996-12-04 1999-01-12 Celltech Therapeutics, Limited Tri-substituted phenyl compounds which have useful pharmaceutical activity
US6599908B1 (en) 1996-12-23 2003-07-29 Celltech R & D Limited Fused polycyclic 2-aminopyrimidine derivatives
US6057329A (en) * 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
US6048866A (en) * 1997-03-14 2000-04-11 Celltech Therapeutics, Limited Substituted 2-anilinopryimidines useful as protein kinase inhibitors
US6337335B1 (en) 1997-03-14 2002-01-08 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
US6133257A (en) * 1997-06-20 2000-10-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
US6943191B1 (en) 1998-02-27 2005-09-13 The United States Of America As Represented By The Department Of Health And Human Services Disubstituted lavendustin A analogs and pharmaceutical composition comprising the analogs
US20040180914A1 (en) * 1999-06-18 2004-09-16 Celltech R&D Limtied 5-Cyano-2-aminopyrimidine derivatives
US6579983B1 (en) 1999-06-18 2003-06-17 Celltech R&D Limited 5-cyano-2-aminopyrimidine derivatives
EP2289549A2 (en) 1999-10-01 2011-03-02 Immunogen, Inc. Immunoconjugates for treating cancer
EP2266607A2 (en) 1999-10-01 2010-12-29 Immunogen, Inc. Immunoconjugates for treating cancer
US6600037B1 (en) 1999-10-20 2003-07-29 Celltech R & D Limited 4,5-disubstituted-2-aminopyrimidines
US20030212269A1 (en) * 1999-10-20 2003-11-13 Davis Jeremy Martin 4.5-disubstituted-2-aminopyrimidines
US20040235876A1 (en) * 1999-10-20 2004-11-25 Celltech R&D Limited 4,5-Disubstituted-2-aminopyrimidines
WO2001046151A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6399636B2 (en) 2000-03-23 2002-06-04 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
US6448274B2 (en) 2000-05-25 2002-09-10 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6677351B2 (en) 2001-05-24 2004-01-13 Merck Frosst Canada & Co. 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
US20040102630A1 (en) * 2001-05-29 2004-05-27 Schering Ag CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents
US20040224966A1 (en) * 2001-05-29 2004-11-11 Thomas Brumby CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7235561B2 (en) 2001-05-29 2007-06-26 Schering Ag Compound and a composition including such a compound
US7291624B2 (en) 2001-05-29 2007-11-06 Bayer Schering Pharma Ag CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents
EP2147679A2 (en) 2001-07-25 2010-01-27 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
WO2003018579A1 (en) 2001-08-29 2003-03-06 Merck Frosst Canada & Co. Alkyne-aryl phosphodiesterase-4 inhibitors
EP2305677A1 (en) 2001-08-29 2011-04-06 Merck Frosst Canada Limited Alkyne-aryl-naphthyridin-4(1h)-one derivatives as type IV phosphodiesterase inhibitor
EP2392258A1 (en) 2005-04-28 2011-12-07 Proteus Biomedical, Inc. Pharma-informatics system
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
WO2006116718A2 (en) 2005-04-28 2006-11-02 Proteus Biomedical, Inc. Pharma-informatics system
EP2258359A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2258357A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2258358A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2275096A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2377530A2 (en) 2005-10-21 2011-10-19 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2382975A2 (en) 2006-05-09 2011-11-02 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2010095940A2 (en) 2009-02-20 2010-08-26 To-Bbb Holding B.V. Glutathione-based drug delivery system
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP4218718A2 (en) 2009-05-06 2023-08-02 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2012044761A1 (en) 2010-09-29 2012-04-05 University Of North Carolina At Wilmington Ladder-frame polyether conjugates
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Also Published As

Publication number Publication date
AU678797B2 (en) 1997-06-12
DE69323732T2 (en) 1999-09-09
CA2129040A1 (en) 1994-07-07
ATE177097T1 (en) 1999-03-15
EP0626957B1 (en) 1999-03-03
JP3581714B2 (en) 2004-10-27
CA2129040C (en) 2004-11-02
DE69323732D1 (en) 1999-04-08
WO1994014800A1 (en) 1994-07-07
JPH07504687A (en) 1995-05-25
ES2131668T3 (en) 1999-08-01
GB9226830D0 (en) 1993-02-17
AU5709394A (en) 1994-07-19
EP0626957A1 (en) 1994-12-07

Similar Documents

Publication Publication Date Title
US5580888A (en) Styryl derivatives as anti-inflammatory agents
US5962483A (en) Trisubstituted phenyl derivatives and processes for their preparation
US5633257A (en) Cyclo(alkyl and alkenyl)phenyl-alkenylyl(aryl and heteroaryl)compounds and pharmaceutical compositions containing them
US5622977A (en) Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
EP0626939B1 (en) Tri-substituted phenyl derivatives as phosphodiesterase inhibitors
US5866593A (en) Trisubstituted phenyl derivatives and processes for their preparation
US5674880A (en) Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) Tri-substituted phenyl or pyridine derivatives
US6077854A (en) Tri-substituted phenyl derivatives and processes for their preparation
US5776958A (en) Trisubstituted phenyl derivatives and processes for their preparation
US5693659A (en) Substituted oxime derivatives and processes for their preparation
US5780478A (en) Tetra-substituted phenyl derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: CELLTECH, LIMITED, ENGLAND

Free format text: CROSS-REFERENCE OF ASSIGNMENT ORIGINALLY RECORDED IN S.N. 08/172,047 AT REEL 7023 FRAME 0720;ASSIGNORS:WARRELLOW, GRAHAM JOHN;BOYD, EWAN CAMPBELL;ALEXANDER, RIKKI PETER;REEL/FRAME:007826/0915

Effective date: 19930712

AS Assignment

Owner name: CELLTECH THERAPEUTICS LIMITED, UNITED KINGDOM

Free format text: CHANGE OF NAME;ASSIGNOR:CELLTECH LIMITED;REEL/FRAME:007879/0798

Effective date: 19941003

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FEPP Fee payment procedure

Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS - SMALL BUSINESS (ORIGINAL EVENT CODE: SM02); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REFU Refund

Free format text: REFUND - PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: R2552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12